false Q2 0000903129 --12-31 Large Accelerated Filer true P3Y us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:AccountingStandardsUpdate201602Member us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember 0000903129 2020-01-01 2020-06-30 xbrli:shares 0000903129 2020-08-03 iso4217:USD 0000903129 2020-06-30 0000903129 2019-12-31 iso4217:USD xbrli:shares 0000903129 2020-04-01 2020-06-30 0000903129 2019-04-01 2019-06-30 0000903129 2019-01-01 2019-06-30 0000903129 2018-12-31 0000903129 2019-06-30 0000903129 us-gaap:CommonStockMember 2019-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000903129 us-gaap:RetainedEarningsMember 2019-12-31 0000903129 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000903129 2020-01-01 2020-03-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000903129 us-gaap:CommonStockMember 2020-03-31 0000903129 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000903129 us-gaap:RetainedEarningsMember 2020-03-31 0000903129 2020-03-31 0000903129 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000903129 us-gaap:CommonStockMember 2020-06-30 0000903129 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000903129 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000903129 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000903129 us-gaap:RetainedEarningsMember 2020-06-30 0000903129 us-gaap:CommonStockMember 2018-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000903129 us-gaap:RetainedEarningsMember 2018-12-31 0000903129 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0000903129 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0000903129 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-01-01 2019-03-31 0000903129 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000903129 2019-01-01 2019-03-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000903129 us-gaap:CommonStockMember 2019-03-31 0000903129 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000903129 us-gaap:RetainedEarningsMember 2019-03-31 0000903129 2019-03-31 0000903129 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000903129 us-gaap:CommonStockMember 2019-06-30 0000903129 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000903129 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000903129 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000903129 us-gaap:RetainedEarningsMember 2019-06-30 xbrli:pure 0000903129 srt:EuropeMember 2020-01-01 2020-06-30 0000903129 thrm:CincinnatiSubZeroProductsLLCMember 2019-01-31 2019-02-01 0000903129 thrm:CincinnatiSubZeroProductsLLCMember 2019-02-01 0000903129 thrm:CincinnatiSubZeroProductsLLCMember 2019-01-01 2019-06-30 0000903129 thrm:GPTMember 2019-04-01 2019-06-30 0000903129 thrm:GPTMember 2019-01-01 2019-06-30 0000903129 thrm:StihlerElectronicGmbHMember 2019-04-01 2019-04-01 0000903129 thrm:StihlerElectronicGmbHMember 2019-04-01 0000903129 thrm:EmployeeSeparationCostsMember thrm:ManufacturingFootprintRationalizationMember 2020-04-01 2020-06-30 0000903129 thrm:EmployeeSeparationCostsMember thrm:ManufacturingFootprintRationalizationMember 2020-01-01 2020-06-30 0000903129 thrm:ManufacturingFootprintRationalizationMember 2020-04-01 2020-06-30 0000903129 thrm:ManufacturingFootprintRationalizationMember 2020-01-01 2020-06-30 0000903129 thrm:AdvancedResearchAndDevelopmentRationalizationAndSiteConsolidationMember 2020-01-01 2020-06-30 0000903129 srt:MinimumMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 srt:MaximumMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 thrm:RestructuringCashPaymentMember srt:MinimumMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 thrm:RestructuringCashPaymentMember srt:MaximumMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 thrm:EmployeeSeparationCostsMember srt:MinimumMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 thrm:EmployeeSeparationCostsMember srt:MaximumMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 thrm:RestructuringCapitalExpendituresMember srt:MinimumMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 thrm:RestructuringCapitalExpendituresMember srt:MaximumMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 thrm:RestructuringAcceleratedDepreciationAndImpairmentMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 us-gaap:OtherRestructuringMember srt:MinimumMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 us-gaap:OtherRestructuringMember srt:MaximumMember thrm:ManufacturingFootprintRationalizationMember 2020-06-30 0000903129 thrm:EmployeeSeparationCostsMember thrm:OtherRestructuringActivitiesMember 2020-04-01 2020-06-30 0000903129 thrm:EmployeeSeparationCostsMember thrm:OtherRestructuringActivitiesMember 2020-01-01 2020-06-30 0000903129 thrm:EmployeeSeparationCostsMember thrm:OtherRestructuringActivitiesMember 2019-04-01 2019-06-30 0000903129 thrm:EmployeeSeparationCostsMember thrm:OtherRestructuringActivitiesMember 2019-01-01 2019-06-30 0000903129 us-gaap:OtherRestructuringMember thrm:OtherRestructuringActivitiesMember 2020-04-01 2020-06-30 0000903129 us-gaap:OtherRestructuringMember thrm:OtherRestructuringActivitiesMember 2020-01-01 2020-06-30 0000903129 us-gaap:OtherRestructuringMember thrm:OtherRestructuringActivitiesMember 2019-04-01 2019-06-30 0000903129 us-gaap:OtherRestructuringMember thrm:OtherRestructuringActivitiesMember 2019-01-01 2019-06-30 0000903129 thrm:OtherRestructuringActivitiesMember 2019-04-01 2019-06-30 0000903129 thrm:OtherRestructuringActivitiesMember 2019-01-01 2019-06-30 0000903129 thrm:GPTAndCSZICMember thrm:EmployeeSeparationCostsMember 2019-04-01 2019-06-30 0000903129 thrm:GPTAndCSZICMember thrm:EmployeeSeparationCostsMember 2019-01-01 2019-06-30 0000903129 thrm:GPTAndCSZICMember us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000903129 thrm:GPTAndCSZICMember us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000903129 thrm:GPTAndCSZICMember 2020-01-01 2020-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2020-04-01 2020-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2019-04-01 2019-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2020-01-01 2020-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2019-01-01 2019-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:IndustrialSegmentsMember 2020-04-01 2020-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:IndustrialSegmentsMember 2019-04-01 2019-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:IndustrialSegmentsMember 2020-01-01 2020-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:IndustrialSegmentsMember 2019-01-01 2019-06-30 0000903129 us-gaap:MaterialReconcilingItemsMember 2020-04-01 2020-06-30 0000903129 us-gaap:MaterialReconcilingItemsMember 2019-04-01 2019-06-30 0000903129 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-06-30 0000903129 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-06-30 0000903129 thrm:EmployeeSeparationCostsMember 2019-12-31 0000903129 us-gaap:OtherRestructuringMember 2019-12-31 0000903129 thrm:EmployeeSeparationCostsMember 2020-01-01 2020-03-31 0000903129 thrm:RestructuringAcceleratedDepreciationMember 2020-01-01 2020-03-31 0000903129 us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000903129 thrm:EmployeeSeparationCostsMember 2020-03-31 0000903129 us-gaap:OtherRestructuringMember 2020-03-31 0000903129 thrm:EmployeeSeparationCostsMember 2020-04-01 2020-06-30 0000903129 thrm:RestructuringAcceleratedDepreciationMember 2020-04-01 2020-06-30 0000903129 us-gaap:OtherRestructuringMember 2020-04-01 2020-06-30 0000903129 thrm:EmployeeSeparationCostsMember 2020-06-30 0000903129 us-gaap:OtherRestructuringMember 2020-06-30 0000903129 thrm:ClimateControlSeatsMember thrm:AutomotiveSegmentsMember 2020-04-01 2020-06-30 0000903129 thrm:ClimateControlSeatsMember thrm:AutomotiveSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:ClimateControlSeatsMember thrm:AutomotiveSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:ClimateControlSeatsMember thrm:AutomotiveSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:SeatHeatersMember thrm:AutomotiveSegmentsMember 2020-04-01 2020-06-30 0000903129 thrm:SeatHeatersMember thrm:AutomotiveSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:SeatHeatersMember thrm:AutomotiveSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:SeatHeatersMember thrm:AutomotiveSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:ElectronicsMember thrm:AutomotiveSegmentsMember 2020-04-01 2020-06-30 0000903129 thrm:ElectronicsMember thrm:AutomotiveSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:ElectronicsMember thrm:AutomotiveSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:ElectronicsMember thrm:AutomotiveSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:AutomotiveCablesMember thrm:AutomotiveSegmentsMember 2020-04-01 2020-06-30 0000903129 thrm:AutomotiveCablesMember thrm:AutomotiveSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:AutomotiveCablesMember thrm:AutomotiveSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:AutomotiveCablesMember thrm:AutomotiveSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:SteeringWheelHeatersMember thrm:AutomotiveSegmentsMember 2020-04-01 2020-06-30 0000903129 thrm:SteeringWheelHeatersMember thrm:AutomotiveSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:SteeringWheelHeatersMember thrm:AutomotiveSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:SteeringWheelHeatersMember thrm:AutomotiveSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:BatteryThermalManagementMember thrm:AutomotiveSegmentsMember 2020-04-01 2020-06-30 0000903129 thrm:BatteryThermalManagementMember thrm:AutomotiveSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:BatteryThermalManagementMember thrm:AutomotiveSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:BatteryThermalManagementMember thrm:AutomotiveSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:OtherAutomotiveMember thrm:AutomotiveSegmentsMember 2020-04-01 2020-06-30 0000903129 thrm:OtherAutomotiveMember thrm:AutomotiveSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:OtherAutomotiveMember thrm:AutomotiveSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:OtherAutomotiveMember thrm:AutomotiveSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:AutomotiveSegmentsMember 2020-04-01 2020-06-30 0000903129 thrm:AutomotiveSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:AutomotiveSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:AutomotiveSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:MedicalMember thrm:IndustrialSegmentsMember 2020-04-01 2020-06-30 0000903129 thrm:MedicalMember thrm:IndustrialSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:MedicalMember thrm:IndustrialSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:MedicalMember thrm:IndustrialSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:GenthermGlobalPowerTechnologiesMember thrm:IndustrialSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:GenthermGlobalPowerTechnologiesMember thrm:IndustrialSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:CincinnatiSubZeroIndustrialChamberBusinessMember thrm:IndustrialSegmentsMember 2019-01-01 2019-06-30 0000903129 thrm:IndustrialSegmentsMember 2020-04-01 2020-06-30 0000903129 thrm:IndustrialSegmentsMember 2019-04-01 2019-06-30 0000903129 thrm:IndustrialSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:IndustrialSegmentsMember 2019-01-01 2019-06-30 0000903129 country:US 2020-04-01 2020-06-30 0000903129 country:US 2019-04-01 2019-06-30 0000903129 country:US 2020-01-01 2020-06-30 0000903129 country:US 2019-01-01 2019-06-30 0000903129 country:CN 2020-04-01 2020-06-30 0000903129 country:CN 2019-04-01 2019-06-30 0000903129 country:CN 2020-01-01 2020-06-30 0000903129 country:CN 2019-01-01 2019-06-30 0000903129 country:KR 2020-04-01 2020-06-30 0000903129 country:KR 2019-04-01 2019-06-30 0000903129 country:KR 2020-01-01 2020-06-30 0000903129 country:KR 2019-01-01 2019-06-30 0000903129 country:DE 2020-04-01 2020-06-30 0000903129 country:DE 2019-04-01 2019-06-30 0000903129 country:DE 2020-01-01 2020-06-30 0000903129 country:DE 2019-01-01 2019-06-30 0000903129 country:JP 2020-04-01 2020-06-30 0000903129 country:JP 2019-04-01 2019-06-30 0000903129 country:JP 2020-01-01 2020-06-30 0000903129 country:JP 2019-01-01 2019-06-30 0000903129 country:CZ 2020-04-01 2020-06-30 0000903129 country:CZ 2019-04-01 2019-06-30 0000903129 country:CZ 2020-01-01 2020-06-30 0000903129 country:CZ 2019-01-01 2019-06-30 0000903129 country:CA 2020-04-01 2020-06-30 0000903129 country:CA 2019-04-01 2019-06-30 0000903129 country:CA 2020-01-01 2020-06-30 0000903129 country:CA 2019-01-01 2019-06-30 0000903129 country:RO 2020-04-01 2020-06-30 0000903129 country:RO 2019-04-01 2019-06-30 0000903129 country:RO 2020-01-01 2020-06-30 0000903129 country:RO 2019-01-01 2019-06-30 0000903129 country:GB 2020-04-01 2020-06-30 0000903129 country:GB 2019-04-01 2019-06-30 0000903129 country:GB 2020-01-01 2020-06-30 0000903129 country:GB 2019-01-01 2019-06-30 0000903129 thrm:OtherCountriesMember 2020-04-01 2020-06-30 0000903129 thrm:OtherCountriesMember 2019-04-01 2019-06-30 0000903129 thrm:OtherCountriesMember 2020-01-01 2020-06-30 0000903129 thrm:OtherCountriesMember 2019-01-01 2019-06-30 0000903129 us-gaap:NonUsMember 2020-04-01 2020-06-30 0000903129 us-gaap:NonUsMember 2019-04-01 2019-06-30 0000903129 us-gaap:NonUsMember 2020-01-01 2020-06-30 0000903129 us-gaap:NonUsMember 2019-01-01 2019-06-30 0000903129 thrm:AutomotiveSegmentMember us-gaap:OperatingSegmentsMember 2019-12-31 0000903129 thrm:IndustrialSegmentsMember 2019-12-31 0000903129 us-gaap:OperatingSegmentsMember 2019-12-31 0000903129 thrm:AutomotiveSegmentMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-06-30 0000903129 us-gaap:OperatingSegmentsMember 2020-01-01 2020-06-30 0000903129 thrm:AutomotiveSegmentMember us-gaap:OperatingSegmentsMember 2020-06-30 0000903129 thrm:IndustrialSegmentsMember 2020-06-30 0000903129 us-gaap:OperatingSegmentsMember 2020-06-30 0000903129 us-gaap:CustomerRelationshipsMember 2020-06-30 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-06-30 0000903129 us-gaap:InProcessResearchAndDevelopmentMember 2020-06-30 0000903129 us-gaap:CustomerRelationshipsMember 2019-12-31 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000903129 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000903129 us-gaap:TradeNamesMember 2020-06-30 0000903129 us-gaap:TradeNamesMember 2019-12-31 0000903129 thrm:DevelopmentStageTechnologyCompanyMember 2020-02-28 2020-02-28 0000903129 thrm:PatentsAndIntellectualPropertyMember 2020-06-19 2020-06-19 0000903129 thrm:PatentsAndIntellectualPropertyMember us-gaap:OtherIncomeMember 2020-06-19 2020-06-19 0000903129 thrm:UnitedStateRevolvingNoteMember 2020-06-30 0000903129 thrm:UnitedStateRevolvingNoteMember 2019-12-31 0000903129 thrm:UnitedStatesRevolvingNoteEuroDenominationsMember 2020-06-30 0000903129 thrm:UnitedStatesRevolvingNoteEuroDenominationsMember 2019-12-31 0000903129 thrm:DEGVietnamLoanMember 2020-06-30 0000903129 thrm:DEGVietnamLoanMember 2019-12-31 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2014-08-07 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2019-06-26 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2019-06-27 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2020-06-30 0000903129 thrm:LettersOfCreditMember us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2020-06-30 0000903129 thrm:SwingLineLoansMember us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2020-06-30 0000903129 thrm:LettersOfCreditMember us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2019-12-31 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2019-06-26 2019-06-26 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2019-06-27 2019-06-27 0000903129 us-gaap:FederalFundsEffectiveSwapRateMember srt:MinimumMember 2020-01-01 2020-06-30 0000903129 us-gaap:FederalFundsEffectiveSwapRateMember srt:MaximumMember 2020-01-01 2020-06-30 0000903129 thrm:UnitedStateBankOfAmericaCreditFacilityMember 2020-01-01 2020-06-30 0000903129 thrm:EuroCurrencyRateLoansMember 2020-01-01 2020-06-30 0000903129 us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-06-30 0000903129 thrm:EuroCurrencyRateLoansMember srt:MinimumMember thrm:CreditAgreementMember 2020-01-01 2020-06-30 0000903129 thrm:EuroCurrencyRateLoansMember srt:MaximumMember thrm:CreditAgreementMember 2020-01-01 2020-06-30 0000903129 thrm:BaseRateLoansMember srt:MinimumMember thrm:CreditAgreementMember 2020-01-01 2020-06-30 0000903129 thrm:BaseRateLoansMember srt:MaximumMember thrm:CreditAgreementMember 2020-01-01 2020-06-30 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2020-03-31 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2020-04-01 2020-06-30 0000903129 thrm:DEGVietnamLoanMember 2020-01-01 2020-06-30 0000903129 thrm:UnitedStateAndEuroDenominatedRevolvingNoteMember 2020-06-30 0000903129 srt:MinimumMember 2020-06-30 0000903129 srt:MaximumMember 2020-06-30 0000903129 srt:MinimumMember us-gaap:LandMember 2020-06-30 0000903129 us-gaap:LandMember srt:MaximumMember 2020-06-30 0000903129 thrm:ForeignCurrencyDerivativesMember 2020-06-30 0000903129 thrm:ForeignCurrencyDerivativesMember 2019-12-31 0000903129 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000903129 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000903129 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000903129 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000903129 us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2020-04-01 2020-06-30 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember 2020-04-01 2020-06-30 0000903129 us-gaap:ForeignCurrencyGainLossMember us-gaap:ForeignExchangeContractMember 2020-04-01 2020-06-30 0000903129 us-gaap:ForeignExchangeContractMember us-gaap:ProductMember 2019-04-01 2019-06-30 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember 2019-04-01 2019-06-30 0000903129 us-gaap:ForeignCurrencyGainLossMember us-gaap:ForeignExchangeContractMember 2019-04-01 2019-06-30 0000903129 us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2020-01-01 2020-06-30 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember 2020-01-01 2020-06-30 0000903129 us-gaap:ForeignCurrencyGainLossMember us-gaap:ForeignExchangeContractMember 2020-01-01 2020-06-30 0000903129 us-gaap:ForeignExchangeContractMember us-gaap:ProductMember 2019-01-01 2019-06-30 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember 2019-01-01 2019-06-30 0000903129 us-gaap:ForeignCurrencyGainLossMember us-gaap:ForeignExchangeContractMember 2019-01-01 2019-06-30 0000903129 us-gaap:InterestRateSwapMember 2020-04-01 2020-06-30 0000903129 us-gaap:InterestRateSwapMember 2019-04-01 2019-06-30 0000903129 us-gaap:InterestRateSwapMember 2020-01-01 2020-06-30 0000903129 us-gaap:InterestRateSwapMember 2019-01-01 2019-06-30 0000903129 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000903129 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000903129 us-gaap:FairValueMeasurementsNonrecurringMember 2020-06-30 0000903129 us-gaap:FairValueMeasurementsNonrecurringMember 2019-12-31 0000903129 2016-12-01 2016-12-31 0000903129 2016-12-31 0000903129 2018-06-30 0000903129 2018-06-01 2018-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2020-03-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2020-04-01 2020-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2020-04-01 2020-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2020-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2019-03-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2019-04-01 2019-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2019-04-01 2019-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2019-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2019-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2020-01-01 2020-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2018-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2019-01-01 2019-06-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 0-21810

GENTHERM INCORPORATED

(Exact name of registrant as specified in its charter)

Michigan |  | 95-4318554
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
21680 Haggerty Road, Northville, MI |  | 48167
(Address of principal executive offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (248) 504-0500

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, no par value | THRM | Nasdaq

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ |  | Accelerated filer | ☐
Non-accelerated filer | ☐ |  | Smaller reporting company | ☐
Emerging growth company | ☐ |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At August 3, 2020, there were 32,654,863 issued and outstanding shares of Common Stock of the registrant.

GENTHERM INCORPORATED

Part I. Financial Information |  | 3
| Item 1. |  | Financial Statements (Unaudited) |  | 3
|  |  | Consolidated Condensed Balance Sheets |  | 3
|  |  | Consolidated Condensed Statements of (Loss) Income |  | 4
|  |  | Consolidated Condensed Statements of Comprehensive (Loss) Income |  | 5
|  |  | Consolidated Condensed Statements of Cash Flows |  | 6
|  |  | Consolidated Condensed Statements of Changes in Shareholders’ Equity |  | 7
|  |  | Notes to Unaudited Consolidated Condensed Financial Statements |  | 8
| Item 2. |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 27
| Item 3. |  | Quantitative and Qualitative Disclosures About Market Risk |  | 42
| Item 4. |  | Controls and Procedures |  | 43
Part II. Other Information |  | 44
| Item 1. |  | Legal Proceedings |  | 44
| Item 1A. |  | Risk Factors |  | 44
| Item 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 46
| Item 6. |  | Exhibits |  | 47
Signatures |  | 48

2

PART I. FINANCIAL INFORMATION

ITEM 1. | FINANCIAL STATEMENTS

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

|  | June 30, 2020 |  |  | December 31, 2019 |
ASSETS |  |  |  |  |  |  |  |
Current Assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 209,170 |  |  | $ | 50,443 |
Restricted cash |  |  | 2,505 |  |  |  | 2,505 |
Accounts receivable, less allowance of $1,800 and $1,193, respectively |  |  | 118,885 |  |  |  | 159,710 |
Inventory: |  |  |  |  |  |  |  |
Raw materials |  |  | 61,762 |  |  |  | 61,323 |
Work in process |  |  | 6,575 |  |  |  | 7,444 |
Finished goods |  |  | 44,293 |  |  |  | 49,712 |
Inventory, net |  |  | 112,630 |  |  |  | 118,479 |
Other current assets |  |  | 36,592 |  |  |  | 42,726 |
Total current assets |  |  | 479,782 |  |  |  | 373,863 |
Property and equipment, net |  |  | 149,240 |  |  |  | 160,605 |
Goodwill |  |  | 64,629 |  |  |  | 64,572 |
Other intangible assets, net |  |  | 48,399 |  |  |  | 49,783 |
Operating lease right-of-use assets |  |  | 12,780 |  |  |  | 11,587 |
Deferred income tax assets |  |  | 57,972 |  |  |  | 57,650 |
Other non-current assets |  |  | 10,568 |  |  |  | 9,326 |
Total assets |  | $ | 823,370 |  |  | $ | 727,386 |
LIABILITIES AND SHAREHOLDERS’ EQUITY |  |  |  |  |  |  |  |
Current Liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 65,521 |  |  | $ | 83,035 |
Current lease liabilities |  |  | 4,184 |  |  |  | 4,586 |
Current maturities of long-term debt |  |  | 2,500 |  |  |  | 2,500 |
Other current liabilities |  |  | 63,805 |  |  |  | 66,583 |
Total current liabilities |  |  | 136,010 |  |  |  | 156,704 |
Long-term debt, less current maturities |  |  | 198,099 |  |  |  | 78,124 |
Pension benefit obligation |  |  | 7,690 |  |  |  | 8,057 |
Non-current lease liabilities |  |  | 10,097 |  |  |  | 6,751 |
Other non-current liabilities |  |  | 2,153 |  |  |  | 5,100 |
Total liabilities |  | $ | 354,049 |  |  | $ | 254,736 |
Shareholders’ equity: |  |  |  |  |  |  |  |
Common Stock: |  |  |  |  |  |  |  |
No par value; 55,000,000 shares authorized 32,639,752 and 32,674,354 issued and outstanding at June 30, 2020 and December 31, 2019, respectively |  |  | 104,113 |  |  |  | 102,507 |
Paid-in capital |  |  | 9,770 |  |  |  | 10,852 |
Accumulated other comprehensive loss |  |  | (47,845 | ) |  |  | (42,441 | )
Accumulated earnings |  |  | 403,283 |  |  |  | 401,732 |
Total shareholders’ equity |  |  | 469,321 |  |  |  | 472,650 |
Total liabilities and shareholders’ equity |  | $ | 823,370 |  |  | $ | 727,386 |

See accompanying notes to the consolidated condensed financial statements.

3

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF (LOSS) INCOME

(In thousands, except per share data)

(Unaudited)

|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Product revenues |  | $ | 136,061 |  |  | $ | 243,326 |  |  | $ | 364,674 |  |  | $ | 501,247 |
Cost of sales |  |  | 109,326 |  |  |  | 170,612 |  |  |  | 271,872 |  |  |  | 353,226 |
Gross margin |  |  | 26,735 |  |  |  | 72,714 |  |  |  | 92,802 |  |  |  | 148,021 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net research and development expenses |  |  | 15,341 |  |  |  | 19,255 |  |  |  | 33,101 |  |  |  | 38,152 |
Selling, general and administrative expenses |  |  | 21,889 |  |  |  | 32,171 |  |  |  | 47,729 |  |  |  | 64,822 |
Restructuring expenses |  |  | (598 | ) |  |  | 1,231 |  |  |  | 3,168 |  |  |  | 3,145 |
Total operating expenses |  |  | 36,632 |  |  |  | 52,657 |  |  |  | 83,998 |  |  |  | 106,119 |
Operating (loss) income |  |  | (9,897 | ) |  |  | 20,057 |  |  |  | 8,804 |  |  |  | 41,902 |
Interest expense, net |  |  | (1,361 | ) |  |  | (1,240 | ) |  |  | (2,109 | ) |  |  | (2,608 | )
Foreign currency loss |  |  | (1,741 | ) |  |  | (804 | ) |  |  | (2,679 | ) |  |  | (601 | )
Gain on sale of business |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,970 |
Impairment loss |  |  | — |  |  |  | (9,885 | ) |  |  | — |  |  |  | (20,369 | )
Other income |  |  | 2,882 |  |  |  | 171 |  |  |  | 3,146 |  |  |  | 314 |
(Loss) earnings before income tax |  |  | (10,117 | ) |  |  | 8,299 |  |  |  | 7,162 |  |  |  | 23,608 |
Income tax expense |  |  | 205 |  |  |  | 5,548 |  |  |  | 5,611 |  |  |  | 12,443 |
Net (loss) income |  | $ | (10,322 | ) |  | $ | 2,751 |  |  | $ | 1,551 |  |  | $ | 11,165 |
Basic (loss) earnings per share |  | $ | (0.32 | ) |  | $ | 0.08 |  |  | $ | 0.05 |  |  | $ | 0.33 |
Diluted (loss) earnings per share |  | $ | (0.32 | ) |  | $ | 0.08 |  |  | $ | 0.05 |  |  | $ | 0.33 |
Weighted average number of shares – basic |  |  | 32,580 |  |  |  | 33,441 |  |  |  | 32,635 |  |  |  | 33,508 |
Weighted average number of shares – diluted |  |  | 32,580 |  |  |  | 33,574 |  |  |  | 32,869 |  |  |  | 33,651 |

See accompanying notes to the consolidated condensed financial statements.

4

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(In thousands)

(Unaudited)

|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Net (loss) income |  | $ | (10,322 | ) |  | $ | 2,751 |  |  | $ | 1,551 |  |  | $ | 11,165 |
Other comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  |  | 5,947 |  |  |  | 3,480 |  |  |  | (2,793 | ) |  |  | (771 | )
Unrealized gain (loss) on foreign currency derivative securities, net of tax |  |  | 1,139 |  |  |  | 232 |  |  |  | (2,611 | ) |  |  | 831 |
Other comprehensive income (loss), net of tax |  |  | 7,086 |  |  |  | 3,712 |  |  |  | (5,404 | ) |  |  | 60 |
Comprehensive (loss) income |  | $ | (3,236 | ) |  | $ | 6,463 |  |  | $ | (3,853 | ) |  | $ | 11,225 |

See accompanying notes to the consolidated condensed financial statements.

5

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |
Operating Activities: |  |  |  |  |  |  |  |
Net income |  | $ | 1,551 |  |  | $ | 11,165 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 20,488 |  |  |  | 22,217 |
Deferred income taxes |  |  | (913 | ) |  |  | 3,070 |
Stock based compensation |  |  | 3,909 |  |  |  | 3,291 |
Defined benefit plan income |  |  | (278 | ) |  |  | (699 | )
Allowance for credit losses |  |  | 605 |  |  |  | 545 |
Loss on sale of property and equipment |  |  | 339 |  |  |  | 227 |
Operating lease expense |  |  | 3,490 |  |  |  | 2,903 |
Impairment loss |  |  | — |  |  |  | 20,369 |
Gain on sale of business |  |  | — |  |  |  | (4,970 | )
Gain on sale of patents |  |  | (1,978 | ) |  |  | — |
Changes in assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable |  |  | 37,805 |  |  |  | (4,021 | )
Inventory |  |  | 5,292 |  |  |  | 1,650 |
Other assets |  |  | 2,888 |  |  |  | 276 |
Accounts payable |  |  | (17,753 | ) |  |  | (9,528 | )
Other liabilities |  |  | (5,218 | ) |  |  | (6,087 | )
Net cash provided by operating activities |  |  | 50,227 |  |  |  | 40,408 |
Investing Activities: |  |  |  |  |  |  |  |
Purchases of property and equipment |  |  | (7,500 | ) |  |  | (13,024 | )
Acquisition of intangible assets |  |  | (3,141 | ) |  |  | — |
Proceeds from the sale of patents and property and equipment |  |  | 1,061 |  |  |  | 82 |
Proceeds from divestiture of business |  |  | — |  |  |  | 47,500 |
Acquisition of subsidiary, net of cash acquired |  |  | — |  |  |  | (15,476 | )
Net cash (used in) provided by investing activities |  |  | (9,580 | ) |  |  | 19,082 |
Financing Activities: |  |  |  |  |  |  |  |
Borrowing of debt |  |  | 201,193 |  |  |  | 28,371 |
Repayments of debt |  |  | (81,830 | ) |  |  | (61,120 | )
Cash paid for financing costs |  |  | — |  |  |  | (1,278 | )
Cash paid for the cancellation of restricted stock |  |  | (471 | ) |  |  | (926 | )
Proceeds from the exercise of Common Stock options |  |  | 6,178 |  |  |  | 4,771 |
Cash paid for the repurchase of Common Stock |  |  | (9,092 | ) |  |  | (33,040 | )
Net cash provided by (used in) financing activities |  |  | 115,978 |  |  |  | (63,222 | )
Foreign currency effect |  |  | 2,102 |  |  |  | 293 |
Net increase (decrease) in cash, cash equivalents and restricted cash |  |  | 158,727 |  |  |  | (3,439 | )
Cash, cash equivalents and restricted cash at beginning of period |  |  | 52,948 |  |  |  | 39,620 |
Cash, cash equivalents and restricted cash at end of period |  | $ | 211,675 |  |  | $ | 36,181 |
Supplemental disclosure of cash flow information: |  |  |  |  |  |  |  |
Cash (refund) paid for taxes |  | $ | (3,117 | ) |  | $ | 3,522 |
Cash paid for interest |  | $ | 1,967 |  |  | $ | 2,712 |

See accompanying notes to the consolidated condensed financial statements.

6

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(In thousands)

(Unaudited)

|  | Six Months Ended June 30, 2020 |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Other |  |  |  |  |  |  |  |  |
|  | Common Stock |  |  | Paid-in |  |  | Comprehensive |  |  | Accumulated |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Loss |  |  | Earnings |  |  | Total |
Balance at December 31, 2019 |  |  | 32,674 |  |  | $ | 102,507 |  |  | $ | 10,852 |  |  | $ | (42,441 | ) |  | $ | 401,732 |  |  | $ | 472,650 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 11,873 |  |  |  | 11,873 |
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (12,490 | ) |  |  | — |  |  |  | (12,490 | )
Stock compensation, net |  |  | 171 |  |  |  | 8,644 |  |  |  | (1,204 | ) |  |  | — |  |  |  | — |  |  |  | 7,440 |
Stock repurchase |  |  | (246 | ) |  |  | (9,092 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (9,092 | )
Balance at March 31, 2020 |  |  | 32,599 |  |  | $ | 102,059 |  |  | $ | 9,648 |  |  | $ | (54,931 | ) |  | $ | 413,605 |  |  | $ | 470,381 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (10,322 | ) |  |  | (10,322 | )
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 7,086 |  |  |  | — |  |  |  | 7,086 |
Stock compensation, net |  |  | 41 |  |  |  | 2,054 |  |  |  | 122 |  |  |  | — |  |  |  | — |  |  |  | 2,176 |
Balance at June 30, 2020 |  |  | 32,640 |  |  | $ | 104,113 |  |  | $ | 9,770 |  |  | $ | (47,845 | ) |  | $ | 403,283 |  |  | $ | 469,321 |

|  | Six Months Ended June 30, 2019 |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Other |  |  |  |  |  |  |  |  |
|  | Common Stock |  |  | Paid-in |  |  | Comprehensive |  |  | Accumulated |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Loss |  |  | Earnings |  |  | Total |
Balance at December 31, 2018 |  |  | 33,857 |  |  | $ | 140,300 |  |  | $ | 14,934 |  |  | $ | (39,500 | ) |  | $ | 363,965 |  |  | $ | 479,699 |
Cumulative effect ASU 2016-02 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  | $ | 261 |  |  |  | 261 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 8,414 |  |  |  | 8,414 |
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (3,652 | ) |  |  | — |  |  |  | (3,652 | )
Stock compensation, net |  |  | (4 | ) |  |  | 2,226 |  |  |  | (421 | ) |  |  | — |  |  |  | — |  |  |  | 1,805 |
Stock repurchase |  |  | (200 | ) |  |  | (8,040 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (8,040 | )
Balance at March 31, 2019 |  |  | 33,653 |  |  | $ | 134,486 |  |  | $ | 14,513 |  |  | $ | (43,152 | ) |  | $ | 372,640 |  |  | $ | 478,487 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,751 |  |  |  | 2,751 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,712 |  |  |  | — |  |  |  | 3,712 |
Stock compensation, net |  |  | 125 |  |  |  | 5,824 |  |  |  | (493 | ) |  |  | — |  |  |  | — |  |  |  | 5,331 |
Stock repurchase |  |  | (630 | ) |  |  | (25,000 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (25,000 | )
Balance at June 30, 2019 |  |  | 33,148 |  |  | $ | 115,310 |  |  | $ | 14,020 |  |  | $ | (39,440 | ) |  | $ | 375,391 |  |  | $ | 465,281 |

See accompanying notes to the consolidated condensed financial statements.

7

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Note 1 – Overview

Gentherm Incorporated is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Unless the context otherwise requires, the terms “Gentherm”, “Company”, “we”, “us” and “our” used herein refer to Gentherm Incorporated and its consolidated subsidiaries. Our products provide solutions for automotive passenger climate comfort and convenience, battery thermal management and cell connecting systems, as well as patient temperature management within the health care industry. Our automotive products can be found in the vehicles of nearly all major automotive manufacturers operating in North America and Europe, and several major automotive manufacturers in Asia. The Company operates in locations aligned with its major customers’ product strategies to provide locally enhanced design, integration and production capabilities. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets.

On February 1, 2019, the Company completed the divestiture of its environmental test equipment business, Cincinnati Sub-Zero industrial chamber business (“CSZ-IC”) and on October 1, 2019, the Company completed the divestiture of its remote power generation systems business, Gentherm Global Power Technologies (“GPT”). The Company’s consolidated condensed financial statements herein include the results of CSZ-IC and GPT through their respective dates of divestiture. CSZ-IC and GPT are not subject to discontinued operations classification.

On April 1, 2019, Gentherm acquired Stihler Electronic GmbH (“Stihler”), a leading developer and manufacturer of patient and blood temperature management systems. The acquisition was accounted for as a business combination.

Basis of Presentation

The unaudited consolidated condensed financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations. The information furnished in the consolidated condensed financial statements include all adjustments (consisting of only normal, recurring adjustments), considered necessary to present fairly the results of operations, financial position and cash flows of the Company. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

Impact of COVID-19

The COVID-19 pandemic has significantly disrupted global economic activity, including the automotive market. The COVID-19 pandemic began in China around December 2019. The impact of the outbreak quickly expanded beyond China and its surrounding region, and has significantly and adversely impacted the entire global economy and automotive market in 2020. During the first quarter of 2020, customer plants in North America and Europe were closed beginning in the second half of March due to the pandemic. This resulted in temporary, partial closures of several of our manufacturing facilities in North America and Europe by the end of March 2020. Customer plants and our manufacturing facilities in Asia were closed for several weeks in February and operated at reduced volumes in March, resuming production to near full capacity by the end of the first quarter, which continued throughout the second quarter. However, during the second quarter of 2020, our manufacturing facilities in North America and Europe remained closed until the last week in May due to the pandemic, gradually resuming production to near full capacity in North America, and to about 70% capacity in Europe by the end of June.

The COVID-19 pandemic had a significant adverse impact on global automotive markets in the second quarter of 2020 and such adverse impact is continuing, driven by supply chain and production disruptions, workforce restrictions, travel restrictions and reduced consumer spending, among other factors, which had significant negative impacts on Gentherm’s financial performance in the first half of 2020. The consequences of the pandemic and adverse impact to the economy continue to evolve and the full extent of the adverse impact on our business and financial statements remains uncertain as of the date of this filing.

8

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. T hese estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances arising from the COVID-19 pandemic that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.

Note 2 – New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Expected Credit Losses

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets held. ASU 2016-13 is effective for annual and interim periods beginning after December 15, 2019. The Company adopted ASU 2016-13 as of January 1, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted.

Cloud Computing Arrangements That Are Service Contracts

In August 2018, the FASB issued ASU 2018-15, “Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” ASU 2018-15 requires implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. ASU 2018-15 is effective for annual and interim periods beginning after December 15, 2019. The Company adopted ASU 2018-15 as of January 1, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result.

Fair Value Measurement

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 removes certain disclosure requirements, including (i) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, (ii) the policy for timing of transfer between levels, and (iii) the valuation processes for Level 3 fair value measurements. ASU 2018-13 also adds new disclosure requirements, including (i) the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for annual and interim periods beginning after December 15, 2019. The Company adopted ASU 2018-13 as of January 1, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result.

Recently Issued Accounting Pronouncements Not Yet Adopted

Retirement Benefits

In August 2018, the FASB issued ASU 2018-14, “Compensation – Retirement Benefits – Defined Benefit Plans – General (Subtopic 715-20): Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans.” ASU 2018-14

9

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

removes certain disclosure requirements, including (i) the amounts in accumulated other comprehensive income expected to be recognized as components of net periodic benefit cost over the next fiscal year, and (ii) the amount and timing of plan assets expected to be returned to the employer. ASU 2018-14 also adds new disclosure requirements, including (i) the weighted-average interest crediting rates for cash balance plans and other plans with promised interest crediting rates and (ii) an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period. ASU 2018-14 is effective for annual periods ending after December 15, 2020. Early adoption of the amendments in this update is permitted. The Company is currently in the process of determining the impact the implementation of ASU 2018-14 will have on the Company’s financial statement note disclosures.

Income Taxes

In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". This ASU simplifies the accounting for income taxes by removing certain exceptions previously included in the guidance. In addition, the ASU provides new guidance on accounting for specific taxes and minor codification improvements. ASU 2019-12 is effective for annual periods ending after December 15, 2020. Early adoption of the amendments in this update is permitted. The Company is currently in the process of determining the impact the implementation of ASU 2019-12 will have on the Company’s financial statements and financial statement note disclosures.

Reference Rate Reform

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting”. ASU 2020-04 provides practical expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments in this update apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued as a result of reference rate reform. These amendments are not applicable to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. ASU No. 2020-04 is effective as of March 12, 2020 through December 31, 2022 and may be applied to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company will adopt this standard when LIBOR is discontinued and does not expect a material impact to its consolidated financial statements.

Note 3 – Acquisitions and Divestitures

In June 2018, Gentherm announced a new strategic plan. An important element of the strategy was the elimination of investments in non-core areas, including GPT and CSZ-IC.

Divestiture of CSZ-IC

On February 1, 2019, the Company completed the sale of CSZ-IC and the former Cincinnati Sub-Zero headquarters facility to Weiss Technik North America, Inc. for total cash proceeds of $47,500, including $2,500 of cash proceeds placed into an escrow account for a period of up to one year as partial security for the Company’s obligations under the sale agreement. The Company recognized a $4,970 pre-tax gain on the sale of CSZ-IC during the six months ended June 30, 2019, which is classified as Gain on sale of business within the consolidated condensed statements of (loss) income. In January 2020, claims were made against the cash proceeds held in the escrow account, which has been maintained in escrow following the expiration of the one-year escrow period. The Company is not able to estimate the possible loss, if any, of amounts held in escrow in connection with such claims. The cash proceeds held in escrow are recorded as restricted cash within the consolidated condensed balance sheets.

Divestiture of GPT

During 2018, the Company determined that GPT met the held for sale criteria. During the first half of 2019, the Company continued to assess the fair value of the GPT disposal group, less costs to sell, at each reporting period. As a result of these fair value

10

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

measurements, the Company recorded impairment loss of $8,885 and $15,883 for the three and six months ended June 30, 2019, respectively. Additionally, the Company determined an equity investment met the held for sale criteria and recognized impairment loss of $1,000 and $4,486 for the three and six months ended June 30, 2019. On October 1, 2019, the Company completed the sale of GPT for a nominal amount.

Acquisition of Stihler

On April 1, 2019, Gentherm acquired Stihler for a purchase price of $15,476, net of cash acquired and including $653 of contingent consideration to be paid upon achievement of a milestone that must be completed by September 2020. In addition, the purchase agreement includes a contingent payment of $653 to be paid if the selling shareholder remains employed by Stihler through December 2020. This amount is being recognized as a component of selling, general and administrative expenses ratably over the service period. The results of operations of Stihler were reported within the Company’s Industrial segment from the date of acquisition. The acquisition was accounted for as a business combination. The purchase price and related allocation were finalized in the fourth quarter of 2019. The pro forma effect of the Stihler acquisition does not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented.

Note 4 – Restructuring

Manufacturing Footprint Rationalization

On September 23, 2019, the Company committed to a restructuring plan to improve the Company’s manufacturing productivity and rationalize its footprint. Under this plan, the Company will relocate and consolidate certain existing automotive manufacturing and, as a result, reduce the number of plants by two. On March 20, 2020, the Company announced the initial phase of this restructuring plan, which includes the consolidation of all North American electronics manufacturing to Celaya, Mexico. This will result in the closure of the Burlington, Canada facility, and the transfer of electronics manufacturing from Acuña, Mexico. During the second quarter of 2020, due to circumstances arising from the COVID-19 pandemic, management adjusted the plan to proactively manage its cash position. Adjustments to the plan have resulted in changes to the estimated number of employee separations and total costs to execute the plan.

During the three and six months ended June 30, 2020, the Company recognized restructuring expense of $(1,691) and $(1,443) for employee separation costs, respectively, $200 and $442 for accelerated depreciation, respectively, and $16 and $16 for other costs, respectively. The net activity is primarily related to a reduction in the estimates of previously recognized employee separation costs. The Company has recorded approximately $5,965 of restructuring expenses since the inception of this program.

The Company expects to incur total costs of between $16,000 and $19,000, of which $13,000 and $16,000 are expected to be cash expenditures. The total expected costs include employee separation costs of between $6,500 and $7,500, capital expenditures of between $3,500 and $4,500 and non-cash expenses for accelerated depreciation and impairment of fixed assets of approximately $3,000. The Company also expects to incur other transition costs including recruiting, relocation, and machinery and equipment move and set up costs of between $3,000 and $4,000. The actions under this plan are expected to be substantially completed by the end of 2021. The actual timing, costs and savings of the plan may differ materially from the Company’s current expectations and estimates.

Other Restructuring Activities

As part of the Company’s continued efforts to optimize its cost structure, the Company has undertaken several discrete restructuring actions. During the three and six months ended June 30, 2020, the Company recognized $860 and $3,914 of employee separation costs, respectively, and $17 and $239 of other related costs, respectively. During the three and six months ended June 30, 2019, the Company recognized $860 and $1,259 of employee separation costs, respectively, and $349 and $349 of other related costs, respectively. In addition, during the three and six months ended June 30, 2019, the Company recognized $0 and $425 of asset impairment loss, respectively. These restructuring expenses were primarily associated with restructuring actions focused on the rotation of our manufacturing footprint to lower cost locations and the reduction of global overhead costs. These discrete restructuring actions are expected to approximate the total cumulative costs for those actions. The Company will continue to explore opportunities

11

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

to improve its future profitability and competitiveness. These actions may result in the recognition of additional restructuring charges that could be material.

GPT and CSZ-IC

Costs associated with the divestiture process were classified as restructuring. During the three and six months ended June 30, 2019, the Company recognized $0 and $251 of employee separation costs, respectively, and $22 and $861 of other related costs, related to the marketing of GPT and CSZ-IC, respectively, which were classified as restructuring. The Company has recorded approximately $2,303 of restructuring expenses since inception of this program and it is considered complete.

Restructuring Expenses By Reporting Segment

The following table summarizes restructuring expense for the three and six months ended June 30, 2020 and 2019 by reporting segment:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Automotive |  | $ | (619 | ) |  | $ | 826 |  |  | $ | 2,503 |  |  | $ | 1,194 |
Industrial |  |  | 4 |  |  |  | 56 |  |  |  | 100 |  |  |  | 1,602 |
Reconciling items |  |  | 17 |  |  |  | 349 |  |  |  | 565 |  |  |  | 349 |
Total |  | $ | (598 | ) |  | $ | 1,231 |  |  | $ | 3,168 |  |  | $ | 3,145 |

Restructuring Liability

Restructuring liabilities are classified as accrued liabilities on the consolidated condensed balance sheets. The following table summarizes restructuring liability for the six months ended June 30, 2020:

|  | Employee Separation Costs |  |  | Accelerated Depreciation Charges |  |  | Other Related Costs |  |  | Total |
Balance at December 31, 2019 |  | $ | 5,994 |  |  | $ | — |  |  | $ | 71 |  |  | $ | 6,065 |
Additions, charged to restructuring expenses |  |  | 3,302 |  |  |  | 242 |  |  |  | 222 |  |  |  | 3,766 |
Cash payments |  |  | (1,932 | ) |  |  | — |  |  |  | (202 | ) |  |  | (2,134 | )
Non-cash utilization |  |  | — |  |  |  | (242 | ) |  |  | — |  |  |  | (242 | )
Currency translation |  |  | (306 | ) |  |  | — |  |  |  | 38 |  |  |  | (268 | )
Balance at March 31, 2020 |  | $ | 7,058 |  |  | $ | — |  |  | $ | 129 |  |  | $ | 7,187 |
Additions, charged to restructuring expenses |  |  | 1,301 |  |  |  | 200 |  |  |  | 33 |  |  |  | 1,534 |
Change in estimate |  |  | (2,132 | ) |  |  | — |  |  |  | — |  |  |  | (2,132 | )
Cash payments |  |  | (1,286 | ) |  |  | — |  |  |  | (173 | ) |  |  | (1,459 | )
Non-cash utilization |  |  | — |  |  |  | (200 | ) |  |  | — |  |  |  | (200 | )
Currency translation |  |  | 175 |  |  |  | — |  |  |  | 46 |  |  |  | 221 |
Balance at June 30, 2020 |  | $ | 5,116 |  |  | $ | — |  |  | $ | 35 |  |  | $ | 5,151 |

12

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Note 5 – (Loss) Earnings Per Share

Basic (loss) earnings per share are computed by dividing net (loss) income by the weighted average number of shares of Common Stock outstanding during the period. The Company’s diluted (loss) earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the diluted (loss) earnings per share, the treasury stock method is used in determining the number of shares assumed to be issued from the exercise of Common Stock equivalents. The Company had a net loss for the three months ended June 30, 2020. As a result, basic and diluted loss per common share were the same, as any potentially dilutive securities would be anti-dilutive.

The following table illustrates (loss) earnings per share and the weighted average shares outstanding used in calculating basic and diluted (loss) earnings per share:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Net (loss) income |  | $ | (10,322 | ) |  | $ | 2,751 |  |  | $ | 1,551 |  |  | $ | 11,165 |
Basic weighted average shares of Common Stock outstanding |  |  | 32,579,549 |  |  |  | 33,440,764 |  |  |  | 32,635,322 |  |  |  | 33,508,479 |
Dilutive effect of stock options, restricted stock awards and restricted stock units |  |  | — |  |  |  | 132,844 |  |  |  | 233,392 |  |  |  | 142,638 |
Diluted weighted average shares of Common Stock outstanding |  |  | 32,579,549 |  |  |  | 33,573,608 |  |  |  | 32,868,714 |  |  |  | 33,651,117 |
Basic (loss) earnings per share |  | $ | (0.32 | ) |  | $ | 0.08 |  |  | $ | 0.05 |  |  | $ | 0.33 |
Diluted (loss) earnings per share |  | $ | (0.32 | ) |  | $ | 0.08 |  |  | $ | 0.05 |  |  | $ | 0.33 |

The following table represents Common Stock issuable upon the exercise of certain stock options that have been excluded from the diluted earnings calculation because the effect of their inclusion would be anti-dilutive.

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2020 |  | 2019 |  |  | 2020 |  |  | 2019 |
Anti-dilutive securities share impact |  | N/A |  |  | 630 |  |  |  | 347 |  |  |  | 630 |

Note 6 – Segment Reporting

Segment information is used by management for making strategic operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss.

The Company’s reportable segments are as follows:

| • | Automotive – this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, specialized automotive cable systems, battery thermal management, and automotive electronic systems.

| • | Industrial – this segment represents the combined results from our patient temperature management systems business (“Medical”), GPT (through October 1, 2019), CSZ-IC (through February 1, 2019) and Gentherm’s advanced research and development division. The operating results from these businesses and division are presented together as one reporting segment because of their historical joint concentration on identifying new markets and product applications based on thermal management technologies.

| • | Reconciling Items – includes corporate selling, general and administrative costs and acquisition transaction costs.

13

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

The tables below present segment information about the reported product revenues, depreciation and amortization and operating income (loss) of the Company for three and six months ended June 30, 2020 and 2019.

Three Months Ended June 30, |  | Automotive |  |  | Industrial |  |  | Reconciling Items |  |  | Consolidated Total |
2020: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenues |  | $ | 124,386 |  |  | $ | 11,675 |  |  | $ | — |  |  | $ | 136,061 |
Depreciation and amortization |  |  | 9,297 |  |  |  | 474 |  |  |  | 311 |  |  |  | 10,082 |
Operating income (loss) |  |  | 1,251 |  |  |  | (158 | ) |  |  | (10,990 | ) |  |  | (9,897 | )
2019: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenues |  | $ | 229,700 |  |  | $ | 13,626 |  |  | $ | — |  |  | $ | 243,326 |
Depreciation and amortization |  |  | 10,327 |  |  |  | 416 |  |  |  | 422 |  |  |  | 11,165 |
Operating income (loss) |  |  | 37,931 |  |  |  | (4,121 | ) |  |  | (13,753 | ) |  |  | 20,057 |

Six Months Ended June 30, |  | Automotive |  |  | Industrial |  |  | Reconciling Items |  |  | Consolidated Total |
2020: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenues |  | $ | 340,858 |  |  | $ | 23,816 |  |  | $ | — |  |  | $ | 364,674 |
Depreciation and amortization |  |  | 18,821 |  |  |  | 981 |  |  |  | 686 |  |  |  | 20,488 |
Operating income (loss) |  |  | 32,612 |  |  |  | (418 | ) |  |  | (23,390 | ) |  |  | 8,804 |
2019: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenues |  | $ | 472,057 |  |  | $ | 29,190 |  |  | $ | — |  |  | $ | 501,247 |
Depreciation and amortization |  |  | 20,490 |  |  |  | 839 |  |  |  | 888 |  |  |  | 22,217 |
Operating income (loss) |  |  | 77,827 |  |  |  | (8,635 | ) |  |  | (27,290 | ) |  |  | 41,902 |

Automotive and Industrial segment product revenues by product category for the three and six months ended June 30, 2020 and 2019 were as follows:

|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Climate Control Seats (CCS) |  | $ | 49,879 |  |  | $ | 88,437 |  |  | $ | 132,407 |  |  | $ | 182,791 |
Seat Heaters |  |  | 33,342 |  |  |  | 73,628 |  |  |  | 97,874 |  |  |  | 147,548 |
Electronics |  |  | 13,488 |  |  |  | 11,454 |  |  |  | 23,864 |  |  |  | 24,306 |
Automotive Cables |  |  | 9,833 |  |  |  | 22,206 |  |  |  | 31,973 |  |  |  | 45,955 |
Steering Wheel Heaters |  |  | 7,980 |  |  |  | 16,029 |  |  |  | 27,215 |  |  |  | 32,999 |
Battery Thermal Management (BTM) |  |  | 6,653 |  |  |  | 8,896 |  |  |  | 17,862 |  |  |  | 19,641 |
Other Automotive |  |  | 3,211 |  |  |  | 9,050 |  |  |  | 9,663 |  |  |  | 18,817 |
Subtotal Automotive |  |  | 124,386 |  |  |  | 229,700 |  |  |  | 340,858 |  |  |  | 472,057 |
Medical |  |  | 11,675 |  |  |  | 9,881 |  |  |  | 23,816 |  |  |  | 18,068 |
GPT |  |  | — |  |  |  | 3,745 |  |  |  | — |  |  |  | 7,704 |
CSZ-IC |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,418 |
Subtotal Industrial |  |  | 11,675 |  |  |  | 13,626 |  |  |  | 23,816 |  |  |  | 29,190 |
Total Company |  | $ | 136,061 |  |  | $ | 243,326 |  |  | $ | 364,674 |  |  | $ | 501,247 |

14

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Total product revenues information by geographic area is as follows (based on shipment destination):

|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
United States |  | $ | 47,097 |  |  | $ | 110,632 |  |  | $ | 153,015 |  |  | $ | 229,086 |
China |  |  | 23,517 |  |  |  | 16,410 |  |  |  | 36,520 |  |  |  | 32,007 |
South Korea |  |  | 20,385 |  |  |  | 15,577 |  |  |  | 36,802 |  |  |  | 30,555 |
Germany |  |  | 9,761 |  |  |  | 20,300 |  |  |  | 26,591 |  |  |  | 43,510 |
Japan |  |  | 9,349 |  |  |  | 20,003 |  |  |  | 25,486 |  |  |  | 38,594 |
Czech Republic |  |  | 5,520 |  |  |  | 10,009 |  |  |  | 15,593 |  |  |  | 22,151 |
Canada |  |  | 3,089 |  |  |  | 10,102 |  |  |  | 11,351 |  |  |  | 20,393 |
Romania |  |  | 2,960 |  |  |  | 6,009 |  |  |  | 10,619 |  |  |  | 12,931 |
United Kingdom |  |  | 1,405 |  |  |  | 6,833 |  |  |  | 8,369 |  |  |  | 15,665 |
Other |  |  | 12,978 |  |  |  | 27,451 |  |  |  | 40,328 |  |  |  | 56,355 |
Total Non-U.S. |  | $ | 88,964 |  |  | $ | 132,694 |  |  | $ | 211,659 |  |  | $ | 272,161 |
Total Company |  | $ | 136,061 |  |  | $ | 243,326 |  |  | $ | 364,674 |  |  | $ | 501,247 |

Note 7 – Revenue Recognition

Contract Balances

The Company has no material contract assets. The Company’s contract liabilities are comprised of material rights in the Automotive segment. The aggregate amount of transaction price allocated to material rights that remained unsatisfied as of June 30, 2020 was $171.

Assets Recognized from the Costs to Obtain a Contract with a Customer

The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year. Total capitalized costs to obtain a contract were $1,800 and $1,893 as of June 30, 2020 and December 31, 2019, respectively. These amounts are recorded in other current assets and are being amortized into product revenues over the expected production life of the program.

Note 8 – Income Taxes

At the end of each interim period, the Company makes its best estimate of the annual expected effective income tax rate and applies that rate to its ordinary year-to-date earnings or loss. The income tax provision or benefit related to unusual or infrequent items, if applicable, that will be separately reported or reported net of their related tax effects are individually computed and recognized in the interim period in which those items occur. In addition, the effect of changes in enacted tax laws or rates, tax status, judgment on the realizability of a beginning-of-the-year deferred tax asset in future years or income tax contingencies is recognized in the interim period in which the change occurs.

15

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

The computation of the annual expected effective income tax rate at each interim period requires certain estimates and assumptions including, but not limited to, the expected pre-tax income (or loss) for the year, projections of the proportion of income (and/or loss) earned and taxed in respective jurisdictions, permanent and temporary differences, and the likelihood of the realizability of deferred tax assets generated in the current year. Jurisdictions with a projected loss for the year or a year-to-date loss for which no tax benefit or expense can be recognized due to a valuation allowance are excluded from the estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the composition and timing of actual earnings compared to annual projections. The estimates used to compute the provision or benefit for income taxes may change as new events occur, additional information is obtained or as our tax environment changes. To the extent that the expected annual effective income tax rate changes, the effect of the change on prior interim periods is included in the income tax provision in the period in which the change in estimate occurs.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was signed into U.S. law. The CARES Act provides a stimulus and assistance package intended to address the impact of the COVID-19 pandemic, including tax relief and government loans, grants and investments. As permitted by the CARES Act, the Company expects to defer the payment of payroll taxes each quarter for the remainder of 2020 to be paid in the fourth quarters of 2021 and 2022.

A summary of the provision for income taxes and the corresponding effective tax rate for the three and six months ended June 30, 2020 and 2019, is shown below:

|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Income tax expense |  | $ | 205 |  |  | $ | 5,548 |  |  | $ | 5,611 |  |  | $ | 12,443 |
(Loss) earnings before income tax |  | $ | (10,117 | ) |  | $ | 8,299 |  |  | $ | 7,162 |  |  | $ | 23,608 |
Effective tax rate |  |  | (2.0 | )% |  |  | 66.9 | % |  |  | 78.3 | % |  |  | 52.7 | %

For the three and six months ended June 30, 2020, the Company recognized a tax expense of $3,383 related to multi-year international audit settlements and closures. For the three and six months ended June 30, 2019, the Company recognized a loss of $9,885 and $20,369, respectively related to a non-deductible impairment loss.

The annual effective tax rates differ from the U.S. statutory rate primarily due to foreign rates which differ from those in the U.S., U.S. taxes on foreign earnings, the realization of certain business tax credits, including research and development and foreign tax credits, the applicable withholding taxes on the projected future repatriations of the earnings from the Company’s non-U.S. operations that are not considered permanently reinvested and the effect of the discrete items described above.

16

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Note 9 – Details of Certain Balance Sheet Components

|  | June 30, 2020 |  |  | December 31, 2019 |
Other current assets: |  |  |  |  |  |  |  |
Notes receivable |  | $ | 12,823 |  |  | $ | 9,963 |
Income tax and other tax receivable |  |  | 9,460 |  |  |  | 17,057 |
Prepaid expenses |  |  | 6,689 |  |  |  | 7,022 |
Billable tooling |  |  | 4,890 |  |  |  | 5,194 |
Derivative financial instruments |  |  | — |  |  |  | 1,242 |
Other |  |  | 2,730 |  |  |  | 2,248 |
Total other current assets |  | $ | 36,592 |  |  | $ | 42,726 |
Other current liabilities: |  |  |  |  |  |  |  |
Liabilities from discounts and rebates |  | $ | 20,145 |  |  | $ | 16,593 |
Accrued employee liabilities |  |  | 18,754 |  |  |  | 26,019 |
Income and other taxes payable |  |  | 5,457 |  |  |  | 3,693 |
Restructuring |  |  | 5,151 |  |  |  | 6,065 |
Accrued warranty |  |  | 2,852 |  |  |  | 4,596 |
Derivative financial instruments |  |  | 2,095 |  |  |  | — |
Other |  |  | 9,351 |  |  |  | 9,617 |
Total other current liabilities |  | $ | 63,805 |  |  | $ | 66,583 |

Note 10 – Goodwill and Other Intangibles

Goodwill

A summary of changes in the carrying amount of goodwill, by operating segment, for the six months ended June 30, 2020 is as follows:

|  | Automotive |  |  | Industrial |  |  | Total |
Balance as of December 31, 2019 |  | $ | 36,938 |  |  | $ | 27,634 |  |  | $ | 64,572 |
Exchange rate impact |  |  | 42 |  |  |  | 15 |  |  |  | 57 |
Balance as of June 30, 2020 |  | $ | 36,980 |  |  | $ | 27,649 |  |  | $ | 64,629 |

17

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Other Intangible Assets

Other intangible assets and accumulated amortization balances as of June 30, 2020 and December 31, 2019 were as follows:

|  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Net Carrying Value |
Definite-lived: |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  | $ | 89,352 |  |  | $ | (54,045 | ) |  | $ | 35,307 |
Technology |  |  | 28,286 |  |  |  | (20,919 | ) |  |  | 7,367 |
Product development costs |  |  | 19,859 |  |  |  | (18,804 | ) |  |  | 1,055 |
Indefinite-lived: |  |  |  |  |  |  |  |  |  |  |  |
Tradenames |  |  | 4,670 |  |  |  | — |  |  |  | 4,670 |
Balance as of June 30, 2020 |  | $ | 142,167 |  |  | $ | (93,768 | ) |  | $ | 48,399 |
|  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Net Carrying Value |
Definite-lived: |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  | $ | 89,208 |  |  | $ | (50,687 | ) |  | $ | 38,521 |
Technology |  |  | 25,106 |  |  |  | (19,866 | ) |  |  | 5,240 |
Product development costs |  |  | 19,911 |  |  |  | (18,559 | ) |  |  | 1,352 |
Indefinite-lived: |  |  |  |  |  |  |  |  |  |  |  |
Tradenames |  |  | 4,670 |  |  |  | — |  |  |  | 4,670 |
Balance as of December 31, 2019 |  | $ | 138,895 |  |  | $ | (89,112 | ) |  | $ | 49,783 |

On February 28, 2020, Gentherm acquired the automotive patents and technology of a development-stage technology company for $3,141. The investment was accounted for as an asset acquisition of defensive intangible assets and will be amortized over six years.

On June 19, 2020, Gentherm sold patents from a non-core business for $2,055. The gain on sale of $1,978 was recorded in Other income on the consolidated condensed statements of (loss) income.

In addition to annual impairment testing, which is performed in the fourth quarter of each fiscal year, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions used in determining fair value, including long-term revenue growth projections, profitability, discount rates, recent market valuations from transactions by comparable companies, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions, requiring interim impairment testing. We are not presently aware of any events or circumstances arising from the COVID-19 pandemic that would require us to revise the carrying value of our assets or liabilities as of June 30, 2020.

18

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Note 11 – Debt

The following table summarizes the Company’s debt as of June 30, 2020 and December 31, 2019:

|  | June 30, 2020 |  |  | December 31, 2019 |
|  | Interest Rate |  |  | Principal Balance |  |  | Interest Rate |  |  | Principal Balance |
Amended Credit Agreement: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. Revolving Note (U.S. Dollar Denominations) |  |  | 1.68 | % |  | $ | 174,000 |  |  |  | 3.05 | % |  | $ | 50,000 |
U.S. Revolving Note (Euro Denominations) |  |  | 1.50 | % |  |  | 19,099 |  |  |  | 1.25 | % |  |  | 21,874 |
DEG Vietnam Loan |  |  | 5.21 | % |  |  | 7,500 |  |  |  | 5.21 | % |  |  | 8,750 |
Total debt |  |  |  |  |  |  | 200,599 |  |  |  |  |  |  |  | 80,624 |
Less: current maturities |  |  |  |  |  |  | (2,500 | ) |  |  |  |  |  |  | (2,500 | )
Long-term debt, less current maturities |  |  |  |  |  | $ | 198,099 |  |  |  |  |  |  | $ | 78,124 |

Amended Credit Agreement

The Company, together with certain direct and indirect subsidiaries, had a credit agreement dated August 7, 2014, as amended (the “Credit Agreement”) which included a revolving credit note (“U.S. Revolving Note”) with a maximum borrowing capacity of $350,000.

On June 27, 2019, the Company entered into an Amended and Restated Credit Agreement (the “Amended Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent. The Amended Credit Agreement amended and restated in its entirety the Credit Agreement. The outstanding principal and interest of the U.S. Revolving Note under the Credit Agreement continued and constitute obligations under the Amended Credit Agreement.

The Amended Credit Agreement increased the U.S. Revolving Note from $350,000 to $475,000 and extended the maturity from March 17, 2021 to June 27, 2024. Subject to specified conditions that the Company does not satisfy as of June 30, 2020, the Company can increase the U.S. Revolving Note or incur secured term loans in an aggregate amount of $175,000. The Amended Credit Agreement also provides $15,000 availability for the issuance of letters of credit and a maximum of $40,000 for swing line borrowing. Any amount of the facility utilized for letters of credit or swing line loans outstanding will reduce the amount available under the Amended Credit Agreement. The Company had no outstanding letters of credit issued under the Amended Credit Agreement as of June 30, 2020 and December 31, 2019.

The U.S. borrowers and guarantors participating in the Amended Credit Agreement also entered into a related amended and restated pledge and security agreement. The amended and restated pledge and security agreement grants a security interest to the lenders in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Amended Credit Agreement, including the stock and membership interests of specified subsidiaries (limited to 66% of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Amended Credit Agreement are unconditionally guaranteed by certain of the Company’s subsidiaries. The Amended Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders.

The Amended Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets, merge with other companies or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and Consolidated Leverage Ratio (based on consolidated EBITDA for the applicable trailing 12-month period as defined in the Amended Credit Agreement) as of the end of any fiscal quarter. The Amended Credit Agreement also contains customary events of default.

19

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Under the Amended Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Eurocurrency rate (“Eurocurrency Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate (0.08% at June 30, 2020) plus 0.50%, Bank of America’s prime rate (3.25% at June 30, 2020), or the Eurocurrency rate plus 1.00%. The rate for Eurocurrency Rate Loans denominated in U.S. Dollars is equal to the London Interbank Offered Rate (0.16% at June 30, 2020). All loans denominated in a currency other than the U.S. Dollar must be Eurocurrency Rate Loans. Interest is payable at least quarterly.

The Applicable Rate varies based on the Consolidated Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Amended Credit Agreement, the lowest and highest possible Applicable Rate is 1.25% and 2.25%, respectively, for Eurocurrency Rate Loans and 0.25% and 1.25%, respectively, for Base Rate Loans.

In March 2020, the Company increased its borrowings under the Amended Credit Agreement by $169,546 as a safeguard to increase its cash position and provide additional financial flexibility due to the COVID-19 pandemic. The proceeds have been and will continue to be used for working capital and for other general corporate purposes permitted by the Amended Credit Agreement. During the second quarter of 2020, the Company repaid a net amount of $32,822 of the amounts outstanding under the Amended Credit Agreement. As of June 30, 2020, inclusive of the net new borrowings, $193,099 was outstanding under the Amended Credit Agreement. Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and Consolidated Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing twelve months calculated for purposes of the Consolidated Leverage Ratio, $159,342 remained available as of June 30, 2020 for additional borrowings under the Amended Credit Agreement subject to specified conditions that Gentherm currently satisfies.

DEG Vietnam Loan

The Company also has a fixed interest rate loan with the German Investment Corporation (“DEG”), a subsidiary of KfW Banking Group, a Germany government-owned development bank. The fixed interest rate senior loan agreement with DEG was used to finance the construction and set up of the Vietnam production facility (“DEG Vietnam Loan”). The DEG Vietnam Loan is subject to semi-annual principal payments that began November 2017 and will end May 2023. Under the terms of the DEG Vietnam Loan, the Company must maintain a minimum Equity Ratio and Enhanced Equity Ratio, as defined by the DEG Vietnam Loan agreement, based on the financial statements of Gentherm’s wholly owned subsidiary, Gentherm Vietnam Co. Ltd.

As of June 30, 2020, the Company was in compliance with the terms of the Amended Credit Agreement and DEG Vietnam Loan.

The scheduled principal maturities of our debt as of June 30, 2020 were as follows:

Year |  | U.S. Revolving Note |  |  | DEG Vietnam Note |  |  | Total |
Remainder of 2020 |  | $ | — |  |  | $ | 1,250 |  |  | $ | 1,250 |
2021 |  |  | — |  |  |  | 2,500 |  |  |  | 2,500 |
2022 |  |  | — |  |  |  | 2,500 |  |  |  | 2,500 |
2023 |  |  | — |  |  |  | 1,250 |  |  |  | 1,250 |
2024 |  |  | 193,099 |  |  |  | — |  |  |  | 193,099 |
Total |  | $ | 193,099 |  |  | $ | 7,500 |  |  | $ | 200,599 |

Note 12 – Leases

The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. The Company also has operating leases for office equipment and automobiles. Excluding land leases, our leases have remaining lease terms ranging from less than one year to twelve years and may include options to extend the lease for an additional term equal to the original term of the lease. Land leases have remaining lease terms that range from 40 to 43 years and some which specify that the end of the lease term is at the discretion of the lessee. The Company does not have lease arrangements with related parties.

20

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Components of lease expense for the three and six months ended June 30, 2020 and 2019 were as follows:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Lease cost: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating lease cost |  | $ | 1,637 |  |  | $ | 1,570 |  |  | $ | 3,223 |  |  | $ | 2,903 |
Short-term lease cost |  |  | 390 |  |  |  | 930 |  |  |  | 899 |  |  |  | 1,885 |
Sublease income |  |  | (39 | ) |  |  | (39 | ) |  |  | (79 | ) |  |  | (52 | )
Total lease cost |  | $ | 1,988 |  |  | $ | 2,461 |  |  | $ | 4,043 |  |  | $ | 4,736 |

Other information related to leases is as follows:

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |
Cash paid for amounts included in the measurement of lease liabilities: |  |  |  |  |  |  |  |
Operating cash flows for operating leases |  | $ | 3,294 |  |  | $ | 2,966 |
Right-of-use lease assets obtained in exchange for lease obligations: |  |  |  |  |  |  |  |
Operating leases |  | $ | 5,477 |  |  | $ | 3,004 |
Gain on sale and leaseback transactions, net |  | $ | — |  |  | $ | 207 |
|  | June 30, 2020 |  |  | June 30, 2019 |
Weighted average remaining lease term: |  |  |  |  |  |  |  |
Operating leases |  | 6.7 years |  |  | 4.7 years |
Weighted average discount rate: |  |  |  |  |  |  |  |
Operating leases |  |  | 5.08 | % |  |  | 5.40 | %

A summary of operating leases as of June 30, 2020, under all non-cancellable operating leases with terms exceeding one year is as follows:

2020 (excluding the six months ended June 30, 2020) |  | $ | 2,691 |
2021 |  |  | 4,263 |
2022 |  |  | 2,083 |
2023 |  |  | 1,269 |
2024 |  |  | 1,259 |
2025 or later |  |  | 5,487 |
Total future minimum lease payments |  |  | 17,052 |
Less imputed interest |  |  | (2,771 | )
Total |  | $ | 14,281 |

21

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Note 13 – Financial Instruments

Cash, Cash Equivalents and Restricted Cash

The Company has cash that is legally restricted as to use or withdrawal. A reconciliation of cash and cash equivalents on the consolidated condensed balance sheets to cash, cash equivalents and restricted cash presented on the consolidated condensed statements of cash flows is as follows:

|  | June 30, 2020 |  |  | December 31, 2019 |
Cash and cash equivalents presented in the consolidated condensed balance sheets |  | $ | 209,170 |  |  | $ | 50,443 |
Restricted cash |  |  | 2,505 |  |  |  | 2,505 |
Cash, cash equivalents and restricted cash presented in the consolidated condensed statements of cash flows |  | $ | 211,675 |  |  | $ | 52,948 |

Derivative Financial Instruments

The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and commodity price fluctuations. Market risks for changes in interest rates relate primarily to its debt obligations under the Amended Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won and Vietnamese Dong.

The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The maximum length of time over which the Company hedges its exposure to foreign currency exchange risks is one year. The Company had foreign currency derivative contracts with a notional value of $15,003 and $14,449 outstanding as of June 30, 2020 and December 31, 2019, respectively.

The Company does not enter into derivative financial instruments for speculative or trading purposes. The Company’s hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of (loss) income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency hedging instruments, if any, to foreign currency gain (loss) in the consolidated condensed statements of (loss) income.

The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounts such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term.

Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of June 30, 2020 is as follows:

|  |  |  |  |  | Asset Derivatives |  |  | Liability Derivatives |  |  |  |  |
|  | Hedge Designation |  | Fair Value Hierarchy |  | Balance Sheet Location |  | Fair Value |  |  | Balance Sheet Location |  | Fair Value |  |  | Net Asset/ (Liabilities) |
Foreign currency derivatives |  | Cash flow hedge |  | Level 2 |  | Other current assets |  | $ | — |  |  | Other current liabilities |  | $ | (2,095 | ) |  | $ | (2,095 | )

22

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of December 31, 2019 is as follows:

|  |  |  |  |  | Asset Derivatives |  |  | Liability Derivatives |  |  |  |  |
|  | Hedge Designation |  | Fair Value Hierarchy |  | Balance Sheet Location |  | Fair Value |  |  | Balance Sheet Location |  | Fair Value |  |  | Net Asset/ (Liabilities) |
Foreign currency derivatives |  | Cash flow hedge |  | Level 2 |  | Other current assets |  | $ | 1,242 |  |  | Other current liabilities |  | $ | — |  |  | $ | 1,242 |

Information relating to the effect of derivative instruments on our consolidated condensed statements of (loss) income is as follows:

|  |  |  | Three Months Ended |  |  | Six Months Ended, |
|  |  |  | June 30, |  |  | June 30, |
|  | Location |  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Foreign currency derivatives |  | Product revenues |  | $ | — |  |  | $ | 435 |  |  | $ | — |  |  | $ | 675 |
|  | Cost of sales |  | $ | (796 | ) |  | $ | — |  |  | $ | (718 | ) |  | $ | — |
|  | Other comprehensive income (loss) |  |  | 1,458 |  |  |  | 297 |  |  |  | (3,337 | ) |  |  | 1,063 |
|  | Foreign currency loss |  |  | (58 | ) |  |  | (32 | ) |  |  | (129 | ) |  |  | (69 | )
Total foreign currency derivatives |  |  |  | $ | 604 |  |  | $ | 700 |  |  | $ | (4,184 | ) |  | $ | 1,669 |

The Company did not incur any hedge ineffectiveness during the three and six months ended June 30, 2020 and 2019.

Note 14 – Fair Value Measurements

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques:

Market: This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Income: This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations.

Cost: This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost).

The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability.

Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Items Measured at Fair Value on a Recurring Basis

Except for derivative instruments (see Note 13), pension plan assets and a corporate owned life insurance policy, the Company had no material financial assets and liabilities that were carried at fair value at June 30, 2020 and December 31, 2019. In determining

23

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value.

Items Measured at Fair Value on a Nonrecurring Basis

The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. As of June 30, 2020 and December 31, 2019, there were no additional significant assets or liabilities measured at fair value on a non-recurring basis.

Items Not Carried at Fair Value

The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of June 30, 2020, and December 31, 2019, the carrying values of the indebtedness under the Company’s Amended Credit Agreement were not materially different than its estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 11). Discount rates used to measure the fair value of the DEG Vietnam Loan are based on quoted swap rates. As of June 30, 2020, the carrying value of the DEG Vietnam Loan was $7,500 as compared to an estimated fair value of $7,694. As of December 31, 2019, the carrying value of the DEG Vietnam Loan was $8,750 as compared to an estimated fair value of $8,785.

Note 15 – Equity

In December 2016, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a three-year, $100 million stock repurchase program (“Stock Repurchase Program”). In June 2018, the Board of Directors authorized an increase of the Stock Repurchase Program to $300 million, and extended the Stock Repurchase Program until December 2020. In March 2020, the Company suspended its Stock Repurchase Program in order to preserve liquidity. However, repurchases under the Stock Repurchase Program may resume at management’s discretion and may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases under the Stock Repurchase Program may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the six months ended June 30, 2020, the Company repurchased approximately $9.1 million of shares with an average price paid per share of $36.93 and, as of June 30, 2020, has a remaining repurchase authorization of approximately $74.2 million. The Company did not make any repurchases under the Stock Repurchase Program during the three months ended June 30, 2020.

24

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

Note 16 – Reclassifications Out of Accumulated Other Comprehensive Income (Loss)

Reclassification adjustments and other activities impacting accumulated other comprehensive income (loss) during the three and six months ended June 30, 2020 and 2019 were as follows:

|  | Defined Benefit Pension Plans |  |  | Foreign Currency Translation Adjustments |  |  | Foreign Currency Hedge Derivatives |  |  |  | Total |
Balance at March 31, 2020 |  | $ | (3,371 | ) |  | $ | (48,705 | ) |  | $ | (2,855 | ) |  |  | $ | (54,931 | )
Other comprehensive income before reclassifications |  |  | — |  |  |  | 5,911 |  |  |  | 572 |  |  |  |  | 6,483 |
Income tax effect of other comprehensive income (loss) before reclassifications |  |  | — |  |  |  | 36 |  |  |  | (125 | ) |  |  |  | (89 | )
Amounts reclassified from accumulated other comprehensive loss into net loss |  |  | — |  |  |  | — |  |  |  | 886 |  | a |  |  | 886 |
Income taxes reclassified into net loss |  |  | — |  |  |  | — |  |  |  | (194 | ) |  |  |  | (194 | )
Net current period other comprehensive income |  |  | — |  |  |  | 5,947 |  |  |  | 1,139 |  |  |  |  | 7,086 |
Balance at June 30, 2020 |  | $ | (3,371 | ) |  | $ | (42,758 | ) |  | $ | (1,716 | ) |  |  | $ | (47,845 | )

| (a) | The amounts reclassified from accumulated other comprehensive income (loss) were included in cost of sales.

|  | Defined Benefit Pension Plans |  |  | Foreign Currency Translation Adjustments |  |  | Foreign Currency Hedge Derivatives |  |  |  | Total |
Balance at March 31, 2019 |  | $ | (2,339 | ) |  | $ | (41,408 | ) |  | $ | 595 |  |  |  | $ | (43,152 | )
Other comprehensive income before reclassifications |  |  | — |  |  |  | 3,477 |  |  |  | 475 |  |  |  |  | 3,952 |
Income tax effect of other comprehensive income (loss) before reclassifications |  |  | — |  |  |  | 3 |  |  |  | (104 | ) |  |  |  | (101 | )
Amounts reclassified from accumulated other comprehensive loss into net income |  |  | — |  |  |  | — |  |  |  | (178 | ) | a |  |  | (178 | )
Income taxes reclassified into net income |  |  | — |  |  |  | — |  |  |  | 39 |  |  |  |  | 39 |
Net current period other comprehensive income |  |  | — |  |  |  | 3,480 |  |  |  | 232 |  |  |  |  | 3,712 |
Balance at June 30, 2019 |  | $ | (2,339 | ) |  | $ | (37,928 | ) |  | $ | 827 |  |  |  | $ | (39,440 | )

| (a) | The amounts reclassified from accumulated other comprehensive income (loss) were included in cost of sales.

|  | Defined Benefit Pension Plans |  |  | Foreign Currency Translation Adjustments |  |  | Foreign Currency Hedge Derivatives |  |  |  | Total |
Balance at December 31, 2019 |  | $ | (3,371 | ) |  | $ | (39,965 | ) |  | $ | 895 |  |  |  | $ | (42,441 | )
Other comprehensive loss before reclassifications |  |  | — |  |  |  | (2,776 | ) |  |  | (3,598 | ) |  |  |  | (6,374 | )
Income tax effect of other comprehensive (loss) income before reclassifications |  |  | — |  |  |  | (17 | ) |  |  | 784 |  |  |  |  | 767 |
Amounts reclassified from accumulated other comprehensive loss into net income |  |  | — |  |  |  | — |  |  |  | 261 |  | a |  |  | 261 |
Income taxes reclassified into net income |  |  | — |  |  |  | — |  |  |  | (58 | ) |  |  |  | (58 | )
Net current period other comprehensive loss |  |  | — |  |  |  | (2,793 | ) |  |  | (2,611 | ) |  |  |  | (5,404 | )
Balance at June 30, 2020 |  | $ | (3,371 | ) |  | $ | (42,758 | ) |  | $ | (1,716 | ) |  |  | $ | (47,845 | )

| (a) | The amounts reclassified from accumulated other comprehensive income (loss) were included in cost of sales.

25

GENTHERM INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentages, share and per share data)

(Unaudited)

|  | Defined Benefit Pension Plans |  |  | Foreign Currency Translation Adjustments |  |  | Foreign Currency Hedge Derivatives |  |  |  | Total |
Balance at December 31, 2018 |  | $ | (2,339 | ) |  | $ | (37,157 | ) |  | $ | (4 | ) |  |  | $ | (39,500 | )
Other comprehensive (loss) income before reclassifications |  |  | — |  |  |  | (597 | ) |  |  | 1,192 |  |  |  |  | 595 |
Income tax effect of other comprehensive loss before reclassifications |  |  | — |  |  |  | (174 | ) |  |  | (260 | ) |  |  |  | (434 | )
Amounts reclassified from accumulated other comprehensive loss into net income |  |  | — |  |  |  | — |  |  |  | (129 | ) | a |  |  | (129 | )
Income taxes reclassified into net income |  |  | — |  |  |  | — |  |  |  | 28 |  |  |  |  | 28 |
Net current period other comprehensive (loss) income |  |  | — |  |  |  | (771 | ) |  |  | 831 |  |  |  |  | 60 |
Balance at June 30, 2019 |  | $ | (2,339 | ) |  | $ | (37,928 | ) |  | $ | 827 |  |  |  | $ | (39,440 | )

| (a) | The amounts reclassified from accumulated other comprehensive income (loss) were included in cost of sales.

The Company expects all of the existing gains and losses related to foreign currency hedge derivatives reported in accumulated other comprehensive loss as of June 30, 2020 to be reclassified into earnings during the next twelve months. See Note 13 for additional information about derivative financial instruments and the effects from reclassification to net (loss) income.

Note 17 – Commitments and Contingencies

The Company may be subject to various legal actions and claims in the ordinary course of its business, including those arising out of breach of contracts, product warranties, product liability, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these matters will not have a material adverse effect on its consolidated condensed results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves, as described below.

Product Liability and Warranty Matters

The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including claims already filed by customers, the warranty accrual is adjusted quarterly to reflect management’s best estimate of future claims. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims in the future or that it will not incur significant costs to defend such claims.

The following is a reconciliation of the changes in accrued warranty costs:

|  | Six Months Ended |
|  | June 30, |
|  | 2020 |  |  | 2019 |
Balance at beginning of the period |  | $ | 4,596 |  |  | $ | 4,514 |
Warranty claims paid |  |  | (1,624 | ) |  |  | (355 | )
Warranty expense for products shipped during the period |  |  | 842 |  |  |  | 1,226 |
Adjustments to warranty estimates from prior periods |  |  | (942 | ) |  |  | (419 | )
Adjustments due to currency translation |  |  | (20 | ) |  |  | 10 |
Balance at end of period |  | $ | 2,852 |  |  | $ | 4,976 |

26

ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our goals, beliefs, plans and expectations about our prospects for the future and other future events, such as the impact of the COVID-19 pandemic on our financial statements, liquidity, and business as well as the global economy, the amount of borrowing availability under the Amended Credit Agreement and the sufficiency of our cash balances and cash generated from operating, investing and financing activities for our future liquidity and capital resource needs, our ability to finance sufficient working capital and our ability to execute our strategic plan and Manufacturing Footprint Rationalization restructuring plan. Reference is made in particular to forward-looking statements included in this “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Such statements may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “anticipate”, “intend”, “continue”, or similar terms, variations of such terms or the negative of such terms. The forward-looking statements included in this Report are made as of the date hereof or as of the date specified herein and are based on management’s current expectations and beliefs. Such statements are subject to a number of assumptions, risks, uncertainties and other factors, which are set forth in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019, Part II “Item 1A. Risk Factors” in this Report and subsequent reports filed with the Securities and Exchange Commission, and which could cause actual results to differ materially from that described in the forward-looking statements. In addition, such forward-looking statements do not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s business and financial results. Except as required by law, we expressly disclaim any obligation or undertaking to update any forward-looking statements to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

The following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, our consolidated condensed financial statements and related notes thereto included elsewhere in this Report and our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2019.

Overview

Gentherm Incorporated is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Unless the context otherwise requires, the terms “Gentherm”, “Company”, “we”, “us” and “our” used herein refer to Gentherm Incorporated and its consolidated subsidiaries. Our products provide solutions for automotive passenger climate comfort and convenience, battery thermal management and cell connecting systems, as well as patient temperature management within the health care industry. Our automotive products can be found in the vehicles of nearly all major automotive manufacturers operating in North America and Europe, and several major automotive manufacturers in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets.

Our sales are driven by the number of vehicles produced by the automotive manufacturers, which is ultimately dependent on consumer demand for automotive vehicles, and our content per vehicle. Historically, new vehicle demand has been driven by macro-economic and other factors, such as interest rates, manufacturer and dealer sales incentives, fuel prices, consumer confidence, employment levels, income growth trends and government and tax incentives. Economic volatility or weakness, as well as geopolitical factors, in North America, Europe or Asia, could result in a significant reduction in automotive sales and production by our customers, which would have an adverse effect on our business, results of operations and financial condition, as we have experienced in the first half of 2020 as a result of the COVID-19 pandemic, as described below. While our diversified automotive OEM customer base and geographic revenue base, along with our flexible cost structure, have well positioned us to withstand the impact of industry downturns, including the current impact of the COVID-19 pandemic, and benefit from industry upturns in the ordinary course, shifts in the mix of global automotive production to higher cost regions or to vehicles with less content could adversely impact our profitability. In addition, we may be adversely impacted by volatility, weakness or slow growth in markets for hybrid electric vehicles specifically.

27

Recent Trends and Economic Conditions

The COVID-19 pandemic has significantly disrupted global economic activity, including the automotive market. The COVID-19 pandemic began in China around December 2019. The impact of the outbreak quickly expanded beyond China and its surrounding region, and has significantly and adversely impacted the entire global economy and automotive market in 2020. During the first quarter of 2020, customer plants in North America and Europe were closed beginning in the second half of March due to the pandemic. This resulted in temporary, partial closures of several of our manufacturing facilities in North America and Europe by the end of March 2020. Customer plants and our manufacturing facilities in Asia were closed for several weeks in February and operated at reduced volumes in March, resuming production to near full capacity by the end of the first quarter, which continued throughout the second quarter. However, during the second quarter of 2020, our manufacturing facilities in North America and Europe remained closed until the last week in May due to the pandemic, gradually resuming production to near full capacity in North America, and to about 70% capacity in Europe by the end of June. The COVID-19 pandemic continued to have a significant impact on global markets in the second quarter of 2020, driven by supply chain and production disruptions, workforce restrictions, travel restrictions and reduced consumer spending, among other factors, which continues to have significant negative impacts on Gentherm’s financial performance, and which may cause the Company to experience continued disruptions that could adversely impact its operations. As the Company ramps up production and brings employees back to work, it has implemented additional health and safety precautions and protocols in response to the pandemic and government guidelines to help ensure the safety and health of all its employees, and it continues to assess and update business continuity plans in the context of this pandemic.

According to the forecasting firm IHS Markit (July 2020 release), global light vehicle production was 12.3 million units in the second quarter of 2020, down 44.3% from 22.1 million units in the second quarter of 2019. For the first half of 2020, global light vehicle production was 30.1 million units, down 33.3% from 45.1 million units in the first half of 2019. With respect to our key markets, IHS Markit (July 2020 release) reports that actual light vehicle production volumes in North America for the second quarter of 2020 were 1.3 million units compared to 4.2 million units in the second quarter of 2019, a decrease of 69.0%, and light vehicle production volumes in Europe were 2.1 million units for the second quarter of 2020 compared to 5.6 million units in the second quarter of 2019, a decrease of 62.5%. Actual light vehicle production volumes in Japan/Korea were 2.0 million units in the second quarter of 2020 compared to 3.4 million units in the second quarter of 2019, a decrease of 41.2%. Actual light vehicle production volumes in China were 6.0 million units in the second quarter of 2020 compared to 5.5 million units in the second quarter of 2019, an increase of 9.1%.

During the second quarter of 2020, Gentherm’s product revenue for our Automotive segment significantly declined in North America and Europe compared to the second quarter of 2019 due to the closure of customer plants and our manufacturing facilities for the majority of the quarter. In the second quarter of 2020, product revenue for our Medical segment increased from the second quarter of 2019 primarily due to increased demand for our Blanketrol® solutions to support temperature management of COVID-19 patients.

IHS Markit (July 2020 release) forecasts of light vehicle production volumes for the full year 2020 is 69.5 million units, down 21.8% from full-year 2019 light vehicle production volumes of 88.9 million. Forecasted light vehicle production volumes are a component of the data we use in forecasting future business. However, due to differences in regional product mix at our manufacturing facilities, as well as releases from customers on specific vehicle programs, our future forecasted results do not always directly correlate with the global and/or regional light vehicle production forecasts of IHS Markit or other third-party sources.

The COVID-19 pandemic significantly adversely affected our operations, results of operations, financial condition, cash flows, liquidity and stock price in the first half of 2020, and such impact may continue for the remainder of 2020. There remains substantial uncertainty regarding the global economic impact of, and the speed and shape of the recovery from, the COVID-19 pandemic, especially for the global automotive industry. In light of the substantial economic and financial impact of the COVID-19 pandemic to date and resulting uncertainties for the remainder of 2020, the Company has taken significant actions to address its liquidity position. In March 2020, the Company borrowed an additional $169 million under its revolving credit facility to increase its cash position and provide additional financial flexibility. During the second quarter of 2020, the Company repaid a net amount of $32.8 million of the amounts outstanding under the Amended Credit Agreement. In addition, the Company has been prudently addressing its day-to-day operations, including reducing expenses, inventory levels and capital spending and deferring a portion of 2020 base salaries generally for salaried employees. In the second half of 2020, as we ramp back up our production, we expect to see a short-term decline in our cash flows due to an increase in our working capital until customer payments are received later in the year. The Company expects that borrowing availability as of the end of the third quarter of 2020 (and potentially thereafter) will be less than as of the end of the second quarter of 2020. See “—Liquidity and Capital Resources” below for additional information.

28

New Business Awards

We believe that innovation is an important element to gaining market acceptance of our products and strengthening our market position. During the second quarter of 2020, we estimate that we secured approximately $300 million of automotive new business awards. Automotive new business awards represent the aggregate projected lifetime revenue of new awards provided by customers to Gentherm in the applicable period, with the value based on the price and volume projections received from each customer as of the award date. Although automotive new business awards are not firm customer orders, we believe that new business awards are an indicator of future revenue. New business awards are not projections of revenue or future business as of June 30, 2020, the date of this Report or any other date. Customer projections regularly change over time and we do not update our calculation of any new business award after the date initially communicated. Automotive new business awards in the second quarter 2020 also do not reflect, in particular, the impact of the COVID-19 pandemic on future business. Revenues resulting from automotive new business awards also are subject to additional risks and uncertainties as described under “Forward-Looking Statements” above.

Divestitures

Divestiture of Cincinnati Sub-Zero industrial chamber business (“CSZ-IC”)

On February 1, 2019, the Company completed the divestiture of CSZ-IC and the former Cincinnati Sub-Zero headquarters facility to Weiss Technik North America, Inc. for total cash proceeds of $47.5 million, including $2.5 million of cash proceeds placed into an escrow account as partial security for the Company’s obligations under the sales agreement. The Company recognized a $5.0 million pre-tax gain on the sale of CSZ-IC during the six months ended June 30, 2019. Cash proceeds of $2.5 million remain in an escrow account pending resolution of claims.

Divestiture of Gentherm Global Power Technologies (“GPT”)

On October 1, 2019, the Company completed the divesture of GPT for a nominal amount.

Acquisitions

Acquisition of Stihler Electronic GmbH (“Stihler”)

On April 1, 2019, Gentherm acquired Stihler, a leading developer and manufacturer of patient and blood temperature management systems, for a purchase price of $15.5 million, net of cash acquired and including $0.7 million of contingent consideration to be paid upon achievement of a milestone that must be completed by September 2020. In addition, the purchase agreement includes a contingent payment of $0.7 million to be paid if the selling shareholder remains employed by Stihler through December 2020, which will be recorded as a component of selling, general and administrative expenses ratably over the service period. The results of operations of Stihler are reported within the Company’s Industrial segment from the date of acquisition.

Restructuring

Manufacturing Footprint Rationalization

On September 23, 2019, the Company committed to a restructuring plan to improve the Company’s manufacturing productivity and rationalize its footprint. Under this plan, the Company will relocate and consolidate certain existing automotive manufacturing and, as a result, reduce the number of plants by two. During the second quarter of 2020, due to circumstances arising from the COVID-19 pandemic, management adjusted the plan to proactively manage its cash position. Adjustments to the plan have resulted in changes to the estimated number of employee separations and total costs to execute the plan. During the three and six months ended June 30, 2020, the Company recognized expense of $(1.7) million and $(1.4) million, respectively, for employee separation costs. Additionally, the Company recognized $0.2 million and $0.5 million, respectively, of accelerated depreciation and other costs during such periods. The net activity is related to a reduction in the estimates of previously recognized employee separation costs. The Company has recorded approximately $6.0 million of restructuring expenses since the inception of this program.

The Company expects to incur total costs of between $16 million and $19 million, of which $13 million and $16 million are expected to be cash expenditures. The total expected costs include employee separation costs of between $6.5 million and $7.5 million, capital expenditures of between $3.5 million and $4.5 million and non-cash expenses for accelerated depreciation and impairment of fixed assets of approximately $3 million. The Company also expects to incur other transition costs including recruiting,

29

relocation, and machinery and equipment move and set up costs of between $3 million and $4 million. The actions under this plan are expected to be substantially completed by the end of 2021. The actual timing, costs and savings of the plan may differ materially from the Company’s current expectations and estimates.

See Note 4, “Restructuring”, to our consolidated condensed financial statements included in this Report for information about our restructuring activities.

GPT and CSZ-IC Restructuring

During 2019, the Company completed its plan to eliminate non-core areas of investment through the divestitures of CSZ-IC and GPT. Costs directly associated with the divestiture process were classified as restructuring expense. During the three and six months ended June 30, 2019, the Company recognized $0 and $0.3 million of employee separation costs, respectively, and less than $0.1 million and $0.8 million of other related costs, respectively.

See Note 4, “Restructuring”, to our consolidated condensed financial statements included in this Report for information about our restructuring activities.

Other Restructuring Activities

As part of the Company’s continued efforts to optimize its cost structure, the Company has undertaken several discrete restructuring actions. During the three and six months ended June 30, 2020, the Company recognized $0.9 million and $4.0 million of employee separation costs, respectively, and less than $0.1 million and $0.2 million of other related costs, respectively. During the three and six months ended June 30, 2019, the Company recognized $0.9 million and $1.3 million of employee separation costs, respectively, and $0.3 million and $0.3 million of other related costs, respectively. In addition, during the three and six months ended June 30, 2019, the Company recognized $0 and $0.4 million of asset impairment loss. These restructuring expenses were primarily associated with restructuring actions focused on the rotation of our manufacturing footprint to lower cost locations and the reduction of global overhead costs. These discrete restructuring actions are expected to approximate the total cumulative costs for those actions. The Company will continue to explore opportunities to improve its future profitability and competitiveness. These actions may result in the recognition of additional restructuring charges that could be material

See Note 4, “Restructuring”, to our consolidated condensed financial statements included in this Report for information about our restructuring activities.

Stock Repurchase Program

In December 2016, the Board of Directors authorized a three-year, $100.0 million stock repurchase program. In June 2018, our Board of Directors authorized an increase in the stock repurchase program to $300.0 million and extended the stock repurchase program until December 2020. In March 2020, the Company suspended its share repurchase program in order to preserve liquidity. However, repurchases under the stock repurchase program may resume at management’s discretion and may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. During the six months ended June 30, 2020, we repurchased approximately $9.1 million of shares and have a remaining repurchase authorization of approximately $74.2 million as of June 30, 2020. We suspended our stock repurchase program to preserve liquidity and did not make any repurchases under the stock repurchase program during the three months ended June 30, 2020.

See Note 15, “Equity”, to our consolidated condensed financial statements included in this Report for information about our stock repurchase program.

Reportable Segments

The Company has two reportable segments for financial reporting purposes: Automotive and Industrial. See Note 6, “Segment Reporting”, to the consolidated condensed financial statements included in this Report for a description of our reportable segments as well as their proportional contribution to the Company’s reported product revenues and operating income. The financial information used by our chief operating decision maker to assess operating performance and allocate resources is based on these reportable segments.

30

Consolidated Results of Operations

The results of operations for the three and six months ended June 30, 2020 and 2019, in thousands, were as follows:

|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |  |  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Product revenues |  | $ | 136,061 |  |  | $ | 243,326 |  |  | $ | (107,265 | ) |  | $ | 364,674 |  |  | $ | 501,247 |  |  | $ | (136,573 | )
Cost of sales |  |  | 109,326 |  |  |  | 170,612 |  |  |  | 61,286 |  |  |  | 271,872 |  |  |  | 353,226 |  |  |  | 81,354 |
Gross margin |  |  | 26,735 |  |  |  | 72,714 |  |  |  | (45,979 | ) |  |  | 92,802 |  |  |  | 148,021 |  |  |  | (55,219 | )
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net research and development expenses |  |  | 15,341 |  |  |  | 19,255 |  |  |  | 3,914 |  |  |  | 33,101 |  |  |  | 38,152 |  |  |  | 5,051 |
Selling, general and administrative expenses |  |  | 21,889 |  |  |  | 32,171 |  |  |  | 10,282 |  |  |  | 47,729 |  |  |  | 64,822 |  |  |  | 17,093 |
Restructuring expenses |  |  | (598 | ) |  |  | 1,231 |  |  |  | 1,829 |  |  |  | 3,168 |  |  |  | 3,145 |  |  |  | (23 | )
Total operating expenses |  |  | 36,632 |  |  |  | 52,657 |  |  |  | 16,025 |  |  |  | 83,998 |  |  |  | 106,119 |  |  |  | 22,121 |
Operating (loss) income |  |  | (9,897 | ) |  |  | 20,057 |  |  |  | (29,954 | ) |  |  | 8,804 |  |  |  | 41,902 |  |  |  | (33,098 | )
Interest expense, net |  |  | (1,361 | ) |  |  | (1,240 | ) |  |  | (121 | ) |  |  | (2,109 | ) |  |  | (2,608 | ) |  |  | 499 |
Foreign currency loss |  |  | (1,741 | ) |  |  | (804 | ) |  |  | (937 | ) |  |  | (2,679 | ) |  |  | (601 | ) |  |  | (2,078 | )
Gain on sale of business |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,970 |  |  |  | (4,970 | )
Impairment loss |  |  | — |  |  |  | (9,885 | ) |  |  | 9,885 |  |  |  | — |  |  |  | (20,369 | ) |  |  | 20,369 |
Other income |  |  | 2,882 |  |  |  | 171 |  |  |  | 2,711 |  |  |  | 3,146 |  |  |  | 314 |  |  |  | 2,832 |
(Loss) earnings before income tax |  |  | (10,117 | ) |  |  | 8,299 |  |  |  | (18,416 | ) |  |  | 7,162 |  |  |  | 23,608 |  |  |  | (16,446 | )
Income tax expense |  |  | 205 |  |  |  | 5,548 |  |  |  | 5,343 |  |  |  | 5,611 |  |  |  | 12,443 |  |  |  | 6,832 |
Net (loss) income |  | $ | (10,322 | ) |  | $ | 2,751 |  |  | $ | (13,073 | ) |  | $ | 1,551 |  |  | $ | 11,165 |  |  | $ | (9,614 | )

Product revenues by product category, in thousands, for the three and six months ended June 30, 2020 and 2019, were as follows:

|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2020 |  |  | 2019 |  |  | % Change |  |  | 2020 |  |  | 2019 |  |  | % Change |
Climate Control Seats (CCS) |  | $ | 49,879 |  |  | $ | 88,437 |  |  |  | (43.6 | )% |  | $ | 132,407 |  |  | $ | 182,791 |  |  |  | (27.6 | )%
Seat Heaters |  |  | 33,342 |  |  |  | 73,628 |  |  |  | (54.7 | )% |  |  | 97,874 |  |  |  | 147,548 |  |  |  | (33.7 | )%
Electronics |  |  | 13,488 |  |  |  | 11,454 |  |  |  | 17.8 | % |  |  | 23,864 |  |  |  | 24,306 |  |  |  | (1.8 | )%
Automotive Cables |  |  | 9,833 |  |  |  | 22,206 |  |  |  | (55.7 | )% |  |  | 31,973 |  |  |  | 45,955 |  |  |  | (30.4 | )%
Steering Wheel Heaters |  |  | 7,980 |  |  |  | 16,029 |  |  |  | (50.2 | )% |  |  | 27,215 |  |  |  | 32,999 |  |  |  | (17.5 | )%
Battery Thermal Management (BTM) |  |  | 6,653 |  |  |  | 8,896 |  |  |  | (25.2 | )% |  |  | 17,862 |  |  |  | 19,641 |  |  |  | (9.1 | )%
Other Automotive |  |  | 3,211 |  |  |  | 9,050 |  |  |  | (64.5 | )% |  |  | 9,663 |  |  |  | 18,817 |  |  |  | (48.6 | )%
Subtotal Automotive |  |  | 124,386 |  |  |  | 229,700 |  |  |  | (45.8 | )% |  |  | 340,858 |  |  |  | 472,057 |  |  |  | (27.8 | )%
Medical |  |  | 11,675 |  |  |  | 9,881 |  |  |  | 18.2 | % |  |  | 23,816 |  |  |  | 18,068 |  |  |  | 31.8 | %
GPT |  |  | — |  |  |  | 3,745 |  |  |  | (100.0 | )% |  |  | — |  |  |  | 7,704 |  |  |  | (100.0 | )%
CSZ-IC |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,418 |  |  |  | (100.0 | )%
Subtotal Industrial |  |  | 11,675 |  |  |  | 13,626 |  |  |  | (14.3 | )% |  |  | 23,816 |  |  |  | 29,190 |  |  |  | (18.4 | )%
Total Company |  |  | 136,061 |  |  |  | 243,326 |  |  |  | (44.1 | )% |  |  | 364,674 |  |  |  | 501,247 |  |  |  | (27.2 | )%

Product Revenues

Below is a summary of our product revenues, in thousands, for the three months ended June 30, 2020 and 2019:

|  | Three Months Ended June 30, |  |  |  | Variance Due To: |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |  |  |  | Volume |  |  | FX |  |  | Pricing/Other |  |  | Total |
Product revenues |  | $ | 136,061 |  |  | $ | 243,326 |  |  | $ | (107,265 | ) |  |  | $ | (99,844 | ) |  | $ | (2,231 | ) |  | $ | (5,190 | ) |  | $ | (107,265 | )

Product revenues for the three months ended June 30, 2020 decreased 44.1% as compared to the three months ended June 30, 2019. The decrease in product revenues is primarily related to reduced volumes in our Automotive segment that we believe resulted substantially from the impact of the COVID-19 pandemic. Product revenues were also negatively impacted by foreign currency

31

impacts, primarily related to the Korean Won, Chinese Renminbi and Euro. The decrease in product revenues included in Variance Due To Pricing/Other above is primarily attributable to the divestitures of GPT on October 1, 2019 and decreases in customer pricing, partially offset by the acquisition of Stihler on April 1, 2019, and growth in Medical primarily due to increased demand for our Blanketrol® solutions to support temperature management of COVID-19 patients.

Below is a summary of our product revenues, in thousands, for the six months ended June 30, 2020 and 2019:

|  | Six Months Ended June 30, |  |  |  | Variance Due To: |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |  |  |  | Volume |  |  | FX |  |  | Pricing/Other |  |  | Total |
Product revenues |  | $ | 364,674 |  |  | $ | 501,247 |  |  | $ | (136,573 | ) |  |  | $ | (117,037 | ) |  | $ | (5,380 | ) |  | $ | (14,156 | ) |  | $ | (136,573 | )

Product revenues for the six months ended June 30, 2020 decreased 27.2% as compared to the six months ended June 30, 2019. The decrease in product revenues is primarily related to reduced volumes in our Automotive segment that we believe resulted substantially from the impact of the COVID-19 pandemic. Product revenues were also negatively impacted by foreign currency impacts, primarily related to the Euro, Korean Won and Chinese Renminbi. The decrease in product revenues included in Variance Due To Pricing/Other above is primarily attributable to the divestitures of CSZ-IC and GPT and decreases in customer pricing, partially offset by the acquisition of Stihler on April 1, 2019 and growth in Medical primarily due to increased demand for our Blanketrol® solutions to support temperature management of COVID-19 patients.

Cost of Sales

Below is a summary of our cost of sales and gross margin, in thousands, for the three months ended June 30, 2020 and 2019:

|  | Three Months Ended June 30, |  |  |  | Variance Due To: |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |  |  |  | Volume |  |  | Operational Performance |  |  | FX |  |  | Other |  |  | Total |
Cost of sales |  | $ | 109,326 |  |  | $ | 170,612 |  |  | $ | 61,286 |  |  |  | $ | 52,153 |  |  | $ | (2,890 | ) |  | $ | 2,640 |  |  | $ | 9,383 |  |  | $ | 61,286 |
Gross margin |  |  | 26,735 |  |  |  | 72,714 |  |  |  | (45,979 | ) |  |  | $ | (47,691 | ) |  | $ | (6,395 | ) |  | $ | 409 |  |  | $ | 7,698 |  |  | $ | (45,979 | )
Gross margin - Percentage of product revenues |  |  | 19.6 | % |  |  | 29.9 | % |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Cost of sales for the three months ended June 30, 2020 decreased 35.9% as compared to the three months ended June 30, 2019. The decrease in cost of sales is primarily related to the impact of the COVID-19 pandemic for our Automotive segment. Favorable foreign currency impacts are primarily attributable to the Mexican Peso, Euro, Ukrainian Hryvnia and Chinese Renminbi. The Operational Performance impact is primarily attributable to a decline in manufacturing productivity related to the COVID-19 pandemic, partially offset by a decrease in material costs. The decrease in cost of sales included in Variance Due to Other above is due to the following items:

| • | $2.6 million of decrease attributable to lower factory costs in North America and Europe related to the temporary closure of our manufacturing facilities during the second quarter due to the COVID-19 pandemic;

| • | $2.5 million of decrease attributable to the divested business of GPT;

| • | $1.8 million of decrease due to lower labor costs due to COVID-19 related furloughs at our manufacturing facilities, as well as social contributions received in China; and

| • | $0.4 million of increase attributable to Medical.

32

Below is a summary of our cost of sales and gross margin, in thousands, for the six months ended June 30, 2020 and 2019:

|  | Six Months Ended June 30, |  |  |  | Variance Due To: |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |  |  |  | Volume |  |  | Operational Performance |  |  | FX |  |  | Other |  |  | Total |
Cost of sales |  | $ | 271,872 |  |  | $ | 353,226 |  |  | $ | 81,354 |  |  |  | $ | 61,879 |  |  | $ | 3,274 |  |  | $ | 4,394 |  |  | $ | 11,807 |  |  | $ | 81,354 |
Gross margin |  |  | 92,802 |  |  |  | 148,021 |  |  |  | (55,219 | ) |  |  | $ | (55,158 | ) |  | $ | (5,711 | ) |  | $ | (986 | ) |  | $ | 6,636 |  |  | $ | (55,219 | )
Gross margin - Percentage of product revenues |  |  | 25.4 | % |  |  | 29.5 | % |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Cost of sales for the six months ended June 30, 2020 decreased 23.0% as compared to the six months ended June 30, 2019. The decrease in cost of sales is primarily related to the impact of the COVID-19 pandemic for our Automotive segment. Favorable foreign currency impacts are primarily attributable to the Mexican Peso, Euro, Ukrainian Hryvnia and Chinese Renminbi. The operational performance improvements are primarily attributable to decrease in material costs. The decrease in cost of sales included in Variance Due to Other above is due to the following items:

| • | $7.7 million of decrease attributable to divested businesses (CSZ-IC and GPT);

| • | $2.6 million of decrease attributable to lower factory costs in North America and Europe during the second quarter of 2020 related to the temporary closure of our manufacturing facilities due to the COVID-19 pandemic;

| • | $2.0 million of increase attributable to Medical, including the impact of the acquisition of Stihler on April 1, 2019; and

| • | $1.8 million of decrease due to lower labor costs in the second quarter of 2020 due to COVID-19 related furloughs at our manufacturing facilities, as well as social contributions received in China.

Net Research and Development Expenses

Below is a summary of our net research and development expenses, in thousands, for the three months ended June 30, 2020 and 2019:

|  | Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Research and development expenses |  | $ | 19,377 |  |  | $ | 24,340 |  |  | $ | 4,963 |
Reimbursed research and development expenses |  |  | (4,036 | ) |  |  | (5,085 | ) |  |  | (1,049 | )
Net research and development expenses |  | $ | 15,341 |  |  | $ | 19,255 |  |  | $ | 3,914 |
Percentage of product revenues |  |  | 11.3 | % |  |  | 7.9 | % |  |  |  |

Net research and development expenses for the three months ended June 30, 2020 decreased 20.3% as compared to the three months ended June 30, 2019. The decrease in net research and development expenses is primarily related to reduced project-related spending due to cost reduction initiatives and lower variable compensation expense, partially offset by lower reimbursements for costs to design, develop and purchase tooling pursuant to customer contracts.

Below is a summary of our net research and development expenses, in thousands, for the six months ended June 30, 2020 and 2019:

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Research and development expenses |  | $ | 39,914 |  |  | $ | 46,948 |  |  | $ | 7,034 |
Reimbursed research and development expenses |  |  | (6,813 | ) |  |  | (8,796 | ) |  |  | (1,983 | )
Net research and development expenses |  | $ | 33,101 |  |  | $ | 38,152 |  |  | $ | 5,051 |
Percentage of product revenues |  |  | 9.1 | % |  |  | 7.6 | % |  |  |  |

Net research and development expenses for the six months ended June 30, 2020 decreased 13.2% as compared to the six months ended June 30, 2019. The decrease in net research and development expenses is primarily related to reduced project-related spending

33

due to cost reduction initiatives and lower variable compensation expense, partially offset by lower reimbursements for costs to design, develop and purchase tooling pursuant to customer contracts.

Selling, General and Administrative Expenses

Below is a summary of our selling, general and administrative expenses, in thousands, for the three months ended June 30, 2020 and 2019:

|  | Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Selling, general and administrative expenses |  | $ | 21,889 |  |  | $ | 32,171 |  |  | $ | 10,282 |
Percentage of product revenues |  |  | 16.1 | % |  |  | 13.2 | % |  |  |  |

Selling, general and administrative expenses for the three months ended June 30, 2020 decreased 32.0% as compared to the three months ended June 30, 2019. The decrease in selling, general and administrative expenses is primarily related to the impacts of the divestiture of GPT, lower variable compensation expense, as well as the impact of cost reduction initiatives and a reduction in travel expenses.

Below is a summary of our selling, general and administrative expenses, in thousands, for the six months ended June 30, 2020 and 2019:

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Selling, general and administrative expenses |  | $ | 47,729 |  |  | $ | 64,822 |  |  | $ | 17,093 |
Percentage of product revenues |  |  | 13.1 | % |  |  | 12.9 | % |  |  |  |

Selling, general and administrative expenses for the six months ended June 30, 2020 decreased 26.4% as compared to the six months ended June 30, 2019. The decrease in selling, general and administrative expenses is primarily related to the impacts of divested businesses (CSZ-IC and GPT), lower variable compensation expense, lower stock compensation expense as a result of mark-to-market revaluation of stock appreciation rights in 2020, the absence of CFO transition costs in 2020, as well as the impact of cost reduction initiatives and a reduction in travel expenses.

Restructuring Expenses

Below is a summary of our restructuring expenses, in thousands, for the three months ended June 30, 2020 and 2019:

|  | Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Restructuring expenses |  | $ | (598 | ) |  | $ | 1,231 |  |  | $ | 1,829 |

Restructuring expenses primarily relate to the Manufacturing Footprint Rationalization restructuring program and other discrete restructuring actions focused on the rotation of our manufacturing footprint to lower cost locations and the reduction of global overhead expenses. During the second quarter of 2020, due to circumstances arising from the COVID-19 pandemic, management adjusted the Manufacturing Footprint Rationalization restructuring plan to proactively manage its cash position.

During the three months ended June 30, 2020, the Company recognized expenses of $(0.8) million for employee separation costs and $0.2 million of accelerated depreciation and other costs. The net activity during the three months ended June 30, 2020 is primarily related to a reduction in the estimates of previously recognized employee separation costs for the Manufacturing Footprint Rationalization restructuring program. During the three months ended June 30, 2019, the Company recognized expenses of $0.9 million for employee separation costs and $0.3 million of other related costs.

Below is a summary of our restructuring expenses, in thousands, for the six months ended June 30, 2020 and 2019:

34

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Restructuring expenses |  | $ | 3,168 |  |  | $ | 3,145 |  |  | $ | (23 | )

Restructuring expenses primarily relate to the Manufacturing Footprint Rationalization restructuring program and other discrete restructuring actions focused on the rotation of our manufacturing footprint to lower cost locations and the reduction of global overhead expenses. During the six months ended June 30, 2020, the Company recognized expenses of $2.5 million for employee separation costs, $0.4 million of accelerated depreciation and $0.3 million of other related costs. During the six months ended June 30, 2019, the Company recognized expenses of $1.5 million for employee separation costs, $0.4 million of asset disposal costs and $1.3 million of other related costs.

See Note 4, “Restructuring” of the consolidated condensed financial statements included in this Report for additional information.

Interest Expense

Below is a summary of our interest expense, in thousands, for the three months ended June 30, 2020 and 2019:

|  | Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Interest expense, net |  | $ | (1,361 | ) |  | $ | (1,240 | ) |  | $ | (121 | )

Below is a summary of our interest expense, in thousands, for the six months ended June 30, 2020 and 2019:

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Interest expense, net |  | $ | (2,109 | ) |  | $ | (2,608 | ) |  | $ | 499 |

See Note 11, “Debt” of the consolidated condensed financial statements included in this Report for additional information.

Foreign Currency (Loss) Gain

Below is a summary of our foreign currency (loss) gain, in thousands, for the three months ended June 30, 2020 and 2019:

|  | Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Foreign currency loss |  | $ | (1,741 | ) |  | $ | (804 | ) |  | $ | (937 | )

Foreign currency loss for the three months ended June 30, 2020 included net realized foreign currency loss of $0.1 million and net unrealized foreign currency loss of $1.6 million.

Foreign currency gain for the three months ended June 30, 2019 included net realized foreign currency loss of $0.7 million and net unrealized foreign currency loss of $0.1 million.

Below is a summary of our foreign currency (loss) gain, in thousands, for the six months ended June 30, 2020 and 2019:

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Foreign currency loss |  | $ | (2,679 | ) |  | $ | (601 | ) |  | $ | (2,078 | )

Foreign currency loss for the three months ended June 30, 2020 included net realized foreign currency loss of $0.3 million and net unrealized foreign currency loss of $2.4 million.

Foreign currency gain for the three months ended June 30, 2019 included net realized foreign currency loss of $1.5 million and net unrealized foreign currency gain of $0.9 million.

35

Gain on Sale of Business

Below is a summary of our gain on sale of business, in thousands, for the six months ended June 30, 2020 and 2019:

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Gain on sale of business |  | $ | — |  |  | $ | 4,970 |  |  | $ | (4,970 | )

On February 1, 2019, as part of the Company’s initiative to eliminate investments in non-core businesses, we completed the sale of CSZ-IC to Weiss Technik North America, Inc. The Company recognized a pre-tax gain of $5.0 million on the sale of CSZ-IC during the six months ended June 30, 2019. The Company did not recognize a gain on sale of business in the six months ended June 30, 2020.

Impairment Loss

Below is a summary of our impairment loss, in thousands, for the three months ended June 30, 2020 and 2019:

|  | Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Impairment loss |  | $ | — |  |  | $ | (9,885 | ) |  | $ | 9,885 |

During the three months ended June 30, 2019, the Company recorded an impairment loss of $9.9 million associated with the divestiture of GPT. See Note 3, “Acquisitions and Divestitures” of the consolidated condensed financial statements included in this Report for additional information.

Below is a summary of our impairment loss, in thousands, for the six months ended June 30, 2020 and 2019:

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Impairment loss |  | $ | — |  |  | $ | (20,369 | ) |  | $ | 20,369 |

During the six months ended June 30, 2019, the Company recorded an impairment loss of $20.4 million associated with the divestiture of GPT. See Note 3, “Acquisitions and Divestitures” of the consolidated condensed financial statements included in this Report for additional information.

Other income

Below is a summary of our other income, in thousands, for the three months ended June 30, 2020 and 2019:

|  | Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Other income |  | $ | 2,882 |  |  | $ | 171 |  |  | $ | 2,711 |

The increase in other income is primarily due to the gain on sale of certain patents from a non-core business in June 2020. See Note 10, “Goodwill and Other Intangibles” of the consolidated condensed financial statements included in this Report for additional information.

Below is a summary of our other income, in thousands, for the six months ended June 30, 2020 and 2019:

36

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Other income |  | $ | 3,146 |  |  | $ | 314 |  |  | $ | 2,832 |

The increase in other income is primarily due to the gain on sale of certain patents from a non-core business in June 2020. See Note 10, “Goodwill and Other Intangibles” of the consolidated condensed financial statements included in this Report for additional information.

Income Tax Expense

Below is a summary of our income tax expense, in thousands, for the three months ended June 30, 2020 and 2019:

|  | Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Income tax expense |  | $ | 205 |  |  | $ | 5,548 |  |  | $ | 5,343 |

Income tax expense was $0.2 million for the three months ended June 30, 2020, on loss before income tax of $10.1 million, representing an effective tax rate of (2.0)%. The tax amount included the effect of the settlement and closure of multi-year international tax audits of $3.4 million. Adjusted for the audit impacts, the effective tax rate was 31.4%. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the international provisions of the U.S. tax law, such as global intangible low-tax income (“GILTI”), partly offset by certain intercompany transactions which disproportionately benefited lower tax rate jurisdictions.

Income tax expense was $5.5 million for the three months ended June 30, 2019, on earnings before income tax of $8.3 million, representing an effective tax rate of 66.9%. The pre-tax earnings amount included the non-deductible impairment loss of $9.9 million. Adjusted for the impairment loss, the effective tax rate was 30.5% for the three months ended June 30, 2019. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the international provisions of the U.S. tax law, such as GILTI, partly offset by certain intercompany transactions which disproportionately benefited lower tax rate jurisdictions.

Below is a summary of our income tax expense, in thousands, for the six months ended June 30, 2020 and 2019:

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | Favorable / (Unfavorable) |
Income tax expense |  | $ | 5,611 |  |  | $ | 12,443 |  |  | $ | 6,832 |

Income tax expense was $5.6 million for the six months ended June 30, 2020, on earnings before income tax of $7.2 million, representing an effective tax rate of 78.4%. The tax amount included the effect of the settlement and closure of multi-year international tax audits of $3.4 million. Adjusted for the audit impacts, the effective tax rate was 31.1%. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the international provisions of the U.S. tax law, such as GILTI, partly offset by certain intercompany transactions which disproportionately benefited lower tax rate jurisdictions.

Income tax expense was $12.4 million for the six months ended June 30, 2019, on earnings before income tax of $23.6 million, representing an effective tax rate of 52.7%. The pre-tax earnings amount included the non-deductible impairment loss of $20.4 million. Adjusted for the impairment loss, the effective tax rate was 28.3% for the six months ended June 30, 2019. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the international provisions of the U.S. tax law, such as GILTI, partly offset by certain intercompany transactions which disproportionately benefited lower tax rate jurisdictions.

Changes in U.S. federal or foreign tax laws and regulations, or their interpretation and application, including those with retroactive effect, could significantly impact our provision for income taxes, the amount of taxes payable, our deferred tax asset and liability balances, and shareholders’ equity. The recently enacted CARES Act, together with earlier issued U.S. Internal Revenue Service guidance, provides for deferral of certain taxes. As permitted by the CARES Act, the Company expects to defer the payment of payroll taxes each quarter for the remainder of 2020 to be paid in the fourth quarters of 2021 and 2022. The Company is evaluating other potential tax benefits under the CARES Act and may be impacted by further government tax guidance or relief.

37

Liquidity and Capital Resources

Cash and Cash Flows

The Company historically has funded its liquidity needs primarily through cash flows from operating activities and equity and debt financings. Prior to the COVID-19 pandemic, we were focused on a capital allocation strategy within our strategic plan that included a targeted debt-to-earnings leverage ratio and using a portion of our cash flow for Common Stock repurchases. As of June 30, 2020, $74.2 million of availability remained under the stock repurchase program.

In light of the significant economic uncertainty and financial impact of the COVID-19 pandemic, the Company has taken significant actions to address its liquidity. First, the Company has been prudently addressing its day-to-day operations, including reducing expenses, inventory levels and capital spending. In addition, effective May 1, 2020, the Company implemented base salary deferrals until December 31, 2020, including a 30-40% deferral at the Executive level and a 20% deferral for other salaried employees, to control expenses and conserve cash. For U.S. employees, the accumulated deferred base salary will generally be paid on or before March 15, 2021 notwithstanding any termination of employment for any reason prior to payment. The Company also revised its non-employee director compensation program for directors elected at the 2020 annual meeting of shareholders, with all compensation being paid in restricted stock for one year. Further, the Company suspended its stock repurchase program in the first quarter of 2020 to preserve liquidity and did not make any repurchases under the stock repurchase program during the three months ended June 30, 2020. Although the Company intends to continue prudently addressing its day-to-day operations to preserve liquidity, as we ramp back up our production in the second half of 2020, we expect to see a short-term decline in our cash flows due to an increase in our working capital until customer payments are received later in the year.

Also, in March 2020, the Company increased its borrowings under the Amended Credit Agreement by $169.5 million as a safeguard to increase its cash position and provide additional financial flexibility. The proceeds have been and will continue to be used for working capital and for other general corporate purposes permitted by the Amended Credit Agreement. During the second quarter of 2020, the Company repaid a net amount of $32.8 million of the amounts outstanding under the Amended Credit Agreement. As of June 30, 2020, inclusive of the net new borrowings, $193.1 million was outstanding under the Amended Credit Agreement. Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and Consolidated Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing twelve months calculated for purposes of the Consolidated Leverage Ratio, $159.3 million remained available as of June 30, 2020 for additional borrowings under the Amended Credit Agreement subject to specified conditions that Gentherm currently satisfies. Subject to any amendment or waiver of the Consolidated Leverage Ratio from the lenders, the Company expects borrowing availability for at least the next twelve months will continue to be significantly less than the full amount of capacity available under the U.S. Revolving Note, and that borrowing availability as of the end of the third quarter of 2020 (and potentially thereafter) will be less than as of the end of the second quarter of 2020, due to the impact of the COVID-19 pandemic and related economic and industry conditions.

The Company may incur additional significant borrowing in the near term. The determination of additional borrowing amounts will be evaluated based upon the Company’s ongoing performance, the current economic and industry outlook and the desire to provide additional financial flexibility. The Company expects that its lenders will agree to an amendment or waiver to increase the borrowing availability if necessary.

Based on the Company’s current operating plan and the foregoing actions, management believes cash and cash equivalents at June 30, 2020, together with cash flows from operating activities, and borrowing available under our Amended Credit Agreement, are sufficient to meet operating and capital expenditure needs, and to service debt, for at least the next 12 months. However, as the impact of the COVID-19 pandemic on the economy and our operations evolves, and cash flows from operations decline, we may need to obtain alternative sources of capital, and we may finance additional liquidity needs in the future through one or more equity or debt offerings.

A continued worldwide disruption could materially affect our future access to sources of liquidity, and there can be no assurance that such capital will be available at all or on reasonable terms. Further, the extent to which the COVID-19 pandemic adversely affects our future financial performance and thus our cash flows will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the pandemic, its severity, the effectiveness of actions to contain the virus or treat its impact and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 pandemic has subsided, we may continue to experience significant adverse impacts on our business, financial

38

performance, financial condition, cash flows, liquidity and stock price for a lengthy period of time as a result of its global economic impact.

The following table represents our cash, cash equivalents and restricted cash, in thousands:

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |
Cash, cash equivalents and restricted cash at beginning of period |  | $ | 52,948 |  |  | $ | 39,620 |
Cash provided by operating activities |  |  | 50,227 |  |  |  | 40,408 |
Cash (used in) provided by investing activities |  |  | (9,580 | ) |  |  | 19,082 |
Cash provided by (used in) financing activities |  |  | 115,978 |  |  |  | (63,222 | )
Foreign currency effect on cash and cash equivalents |  |  | 2,102 |  |  |  | 293 |
Cash, cash equivalents and restricted cash at end of period |  | $ | 211,675 |  |  | $ | 36,181 |

Cash Flows From Operating Activities

We manage our cash, cash equivalents and restricted cash in order to fund operating requirements and preserve liquidity to take advantage of future business opportunities and for financial flexibility. The following table compares the cash flows from operating activities during the six months ended June 30, 2020 as compared to the six months ended June 30, 2019, in thousands:

|  | Six Months Ended June 30, |  |  |  |  |
|  | 2020 |  |  | 2019 |  |  | Change |
Operating Activities: |  |  |  |  |  |  |  |  |  |  |  |
Net income |  | $ | 1,551 |  |  | $ | 11,165 |  |  | $ | (9,614 | )
Non-cash adjustments to reconcile net income to cash provided by operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 20,488 |  |  |  | 22,217 |  |  |  | (1,729 | )
Deferred income taxes |  |  | (913 | ) |  |  | 3,070 |  |  |  | (3,983 | )
Stock based compensation |  |  | 3,909 |  |  |  | 3,291 |  |  |  | 618 |
Defined benefit pension plan income |  |  | (278 | ) |  |  | (699 | ) |  |  | 421 |
Allowance for credit losses |  |  | 605 |  |  |  | 545 |  |  |  | 60 |
Loss on sale of property and equipment |  |  | 339 |  |  |  | 227 |  |  |  | 112 |
Operating lease expense |  |  | 3,490 |  |  |  | 2,903 |  |  |  | 587 |
Impairment loss |  |  | — |  |  |  | 20,369 |  |  |  | (20,369 | )
Gain on sale of business |  |  | — |  |  |  | (4,970 | ) |  |  | 4,970 |
Gain on sale of patents |  |  | (1,978 | ) |  |  | — |  |  |  | (1,978 | )
Net income before non-cash adjustments |  |  | 27,213 |  |  |  | 58,118 |  |  |  | (30,905 | )
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  | 37,805 |  |  |  | (4,021 | ) |  |  | 41,826 |
Inventory |  |  | 5,292 |  |  |  | 1,650 |  |  |  | 3,642 |
Other assets |  |  | 2,888 |  |  |  | 276 |  |  |  | 2,612 |
Accounts payable |  |  | (17,753 | ) |  |  | (9,528 | ) |  |  | (8,225 | )
Other liabilities |  |  | (5,218 | ) |  |  | (6,087 | ) |  |  | 869 |
Net cash provided by operating activities |  | $ | 50,227 |  |  | $ | 40,408 |  |  | $ | 9,819 |

The following table highlights significant differences between the operating cash flows for the six months ended June 30, 2020 and 2019, in thousands:

Net cash provided by operating activities for the six months ended June 30, 2019 |  | $ | 40,408 |
Lower net income before changes in operating assets and liabilities |  |  | (30,905 | )
Changes in working capital, net |  |  | 42,099 |
Changes in other assets and liabilities |  |  | (1,375 | )
Net cash provided by operating activities for the six months ended June 30, 2020 |  | $ | 50,227 |

39

The following table illustrates changes in working capital during the six months ended June 30, 2020, in thousands:

Working capital at December 31, 2019 |  | $ | 217,159 |
Increase in cash, cash equivalents and restricted cash |  |  | 159,225 |
Decrease in accounts receivable |  |  | (39,971 | )
Decrease in inventory |  |  | (5,161 | )
Decrease in tax receivables, net |  |  | (8,772 | )
Increase in other assets |  |  | 2,000 |
Decrease in accounts payable |  |  | 16,800 |
Decrease in accrued expenses and other liabilities |  |  | 3,809 |
Foreign currency effect on working capital |  |  | (1,317 | )
Working capital at June 30, 2020 |  | $ | 343,772 |

The following table highlights significant transactions that contributed to the increase in cash, cash equivalents and restricted cash during the six months ended June 30, 2020, in thousands:

Net cash provided by operating activities |  | $ | 50,227 |
Borrowing of debt |  |  | 201,193 |
Repayments of debt |  |  | (81,830 | )
Cash paid for the repurchase of Common Stock |  |  | (9,092 | )
Purchases of property and equipment |  |  | (7,500 | )
Proceeds from the exercise of Common Stock options |  |  | 6,178 |
Other items |  |  | (449 | )
Increase in cash, cash equivalents and restricted cash |  | $ | 158,727 |

Cash Flows From Investing Activities

Cash used in investing activities was $9.6 million during the six months ended June 30, 2020, primarily reflecting purchases of property and equipment of $7.5 million and the acquisition of intangible assets of $3.1 million.

Cash Flows From Financing Activities

Cash provided by financing activities was $116.0 million during the six months ended June 30, 2020, reflecting additional borrowings on the U.S. Revolving Note totaling $201.2 million partially offset by payments of principal on the U.S. Revolving Note totaling $81.8 million in aggregate. Borrowings under the Amended Credit Agreement mature on June 27, 2024. See Note 11, “Debt” of the consolidated condensed financial statements included in this Report for additional information. Cash was also paid during the six months ended June 30, 2020 for the repurchase of Common Stock totaling $9.1 million and for cancellations of restricted stock awards totaling $0.5 million, partially offset by proceeds from the exercise of Common Stock options totaling $6.2 million.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. For discussion of our significant accounting policies, see Note 2, “Summary of Significant Accounting Policies,” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. There have been no significant changes in our critical accounting policies or critical accounting estimates during the first half of 2020. We are not presently aware of any events or circumstances arising from the COVID-19 pandemic that would require us to update our estimates, assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. For information on the impact of recently issued accounting pronouncements, see Note 2, “New Accounting Pronouncements” in the consolidated condensed financial statements included in this Report.

40

Off-Balance Sheet Arrangements

At June 30, 2020, we do not have any off-balance sheet arrangements that have, or are, in the opinion of management, reasonably likely to have, a current or future material effect on our financial condition or results of operations.

Effects of Inflation

The automotive component supply industry is subject to inflationary pressures with respect to raw materials and labor, which have historically placed operational and financial burdens on the entire supply chain. Accordingly, the Company continues to take actions with its customers and suppliers to mitigate the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with customers include collaboration on alternative product designs and material specifications, contractual price escalation clauses and negotiated customer recoveries. Actions to mitigate inflationary pressures with suppliers include aggregation of purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that it will be successful in fully offsetting increased costs resulting from inflationary pressure.

41

ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our exposure to market risk for changes in interest rates relates primarily to our debt obligations and foreign currency contracts. We have in the past, and may in the future, place our investments in bank certificates of deposits, debt instruments of the U.S. government, and in high-quality corporate issuers.

We are exposed to market risk from changes in foreign currency exchange rates, short-term interest rates and price fluctuations of certain material commodities. Market risks for changes in interest rates relate primarily to our debt obligations under our Amended Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won and Vietnamese Dong.

The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The maximum length of time over which we hedge our exposure to foreign currency exchange risks is one year. We had foreign currency derivative contracts with a notional value of $15.0 million and $14.4 million outstanding at June 30, 2020 and December 31, 2019, respectively.

We do not enter into derivative financial instruments for speculative or trading purposes. Our hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of (loss) income on the same line as the gain or loss on the hedged item attributable to the hedged risk. We record the ineffective portion of foreign currency hedging instruments, if any, to foreign currency (loss) gain in the consolidated condensed statements of (loss) income. Though we continuously monitor the hedging program, derivative positions and hedging strategies, foreign currency forward exchange agreements have not always been designated as hedging instruments for accounting purposes.

The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounts such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term.

Information related to the fair values of all derivative instruments in our consolidated condensed balance sheet as of June 30, 2020 is set forth in Note 13, “Financial Instruments” in the consolidated condensed financial statements included in this Report.

Interest Rate Sensitivity

The table presents principal cash flows and related weighted average interest rates by expected maturity dates for each of the Company’s debt obligations. The information is presented in U.S. dollar equivalents, which is the Company’s reporting currency. The instruments actual cash flows are denominated in U.S. dollars ($USD) or Euros (€EUR), as indicated in parentheses.

|  | Expected Maturity Date |
|  | 2020 |  |  | 2021 |  |  | 2022 |  |  | 2023 |  |  | 2024 |  |  | 2025 |  |  | Total |  |  | Fair Value |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Long-Term Debt: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Variable rate (€EUR) |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 19,099 |  |  | $ | — |  |  | $ | 19,099 |  |  | $ | 19,099 |
Variable interest rate as of June 30, 2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.50 | % |  |  |  |  |  |  | 1.50 | % |  |  |  |
Variable rate ($USD) |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 174,000 |  |  | $ | — |  |  | $ | 174,000 |  |  | $ | 174,000 |
Variable interest rate as of June 30, 2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.68 | % |  |  |  |  |  |  | 1.68 | % |  |  |  |
Fixed rate ($USD) |  | $ | 1,250 |  |  | $ | 2,500 |  |  | $ | 2,500 |  |  | $ | 1,250 |  |  | $ | — |  |  | $ | — |  |  | $ | 7,500 |  |  | $ | 7,694 |
Fixed interest rate |  |  | 5.21 | % |  |  | 5.21 | % |  |  | 5.21 | % |  |  | 5.21 | % |  |  |  |  |  |  |  |  |  |  | 5.21 | % |  |  |  |

42

Exchange Rate Sensitivity

The table below provides information about the Company’s foreign currency forward exchange rate agreements that are sensitive to changes in foreign currency exchange rates. The table presents the notional amounts and weighted average exchange rates by expected (contractual) maturity dates for each type of foreign currency forward exchange agreement. These notional amounts generally are used to calculate the contractual payments to be exchanged under the contract.

|  | Expected Maturity or Transaction Date |
Anticipated Transactions and Related Derivatives |  | 2020 |  |  | Total |  |  | Fair Value |
USD Functional Currency |  |  |  |  |  |  |  |  |  |  |  |
Forward Exchange Agreements: |  |  |  |  |  |  |  |  |  |  |  |
(Receive $MXN / Pay $USD) |  |  |  |  |  |  |  |  |  |  |  |
Total contract amount |  | $ | (15,003 | ) |  | $ | (15,003 | ) |  | $ | (2,095 | )
Average contract rate |  |  | 20.00 |  |  |  | 20.00 |  |  |  |  |

ITEM 4. | CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company maintains disclosure controls and procedures that are designed to provide reasonable assurance of achieving their objectives.

The Company’s management, with the participation of the Chief Executive Officer and the Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective to provide reasonable assurance that the desired control objectives were achieved as of June 30, 2020.

(b) Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the three months ending June 30, 2020, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

43

PART II OTHER INFORMATION

ITEM 1. | LEGAL PROCEEDINGS

We are subject to litigation from time to time in the ordinary course of business, however there is no material pending litigation to which we are a party and no material legal proceeding was terminated, settled or otherwise resolved during the three months ended June 30, 2020.

ITEM 1A. | RISK FACTORS

You should carefully consider the risk factors below and previously disclosed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019.

The COVID-19 pandemic and measures taken to contain it have significantly adversely affected, and are likely to continue to significantly adversely affect, our business, results of operations, financial condition, cash flows, liquidity and stock price.

The COVID-19 pandemic has significantly and adversely impacted the global economy and financial markets, with global legislative and regulatory responses including unprecedented monetary and fiscal policy actions across all sectors, and there is significant uncertainty as to timing of stabilization and recovery. Our business, results of operations, financial condition, cash flows, liquidity and stock price were significantly adversely affected by the COVID-19 pandemic in the first half of 2020, especially beginning in March, and are expected to continue to be significantly adversely affected. The full extent to which the COVID-19 pandemic will impact our business, results of operations, financial condition, cash flows, liquidity and stock price, with regards to scope and duration, are highly uncertain and cannot be predicted with confidence. In particular, if COVID-19 continues to spread or re-emerges, resulting in an extended period of travel, commercial, social and other similar restrictions, we could experience prolonged and significant adverse impacts to our business, results of operations, financial condition, cash flows, liquidity and stock price.

The COVID-19 pandemic and measures taken to contain it have subjected our business, results of operations, financial condition, cash flows, liquidity and stock price to a number of material risks and uncertainties, including, but not limited to:

| ▪ | Risks Related to our Liquidity. In March 2020, we borrowed $169.5 million as a safeguard to provide additional financial flexibility. During the second quarter of 2020, we repaid a net amount of $32.8 million of the amounts outstanding under the Amended Credit Agreement. As of June 30, 2020, our consolidated indebtedness was $200.6 million. Our increased indebtedness has and will continue to result in, among other things, increased interest expense and increased vulnerability to future adverse economic and industry conditions. We may incur additional significant borrowing in the near term, which would increase risks related to indebtedness. In addition, future borrowing availability under our Amended Credit Agreement is subject to our compliance with financial covenants thereunder (including the Consolidated Leverage Ratio based on consolidated EBITDA for the applicable trailing 12-month period). Based upon consolidated EBITDA for the twelve months ended June 30, 2020, $159.3 million remains available for additional borrowings under the Amended Credit Agreement subject to specified conditions that Gentherm currently satisfies. We expect our consolidated EBITDA for the trailing 12-months to be significantly reduced as of the end of the third quarter 2020 due to the COVID-19 impact and it may continue to deteriorate thereafter. Therefore, subject to any amendment or waiver of the Consolidated Leverage Ratio from the lenders, we expect borrowing availability for at least the next twelve months will continue to be significantly less than the full amount of capacity available under the U.S. Revolving Note, and that borrowing availability as of the end of the third quarter of 2020 (and potentially thereafter) will be less than as of the end of the second quarter of 2020. Failure to satisfy certain covenants in the Amended Credit Agreement would result in an event of default, following which our lenders could declare all amounts outstanding to be immediately due and payable and there is no guarantee that we would be able to repay, refinance, or restructure the payments on such debt on acceptable terms or at all. Further, under the Amended Credit Agreement, the lenders would have the right to foreclose on certain of our assets, which could have a significant adverse effect on our business, results of operations, financial condition, cash flows, liquidity and stock price. We may finance additional liquidity needs in the future through one or more equity or debt offerings. The current disruption of the global financial markets could reduce our ability to access additional capital on acceptable terms or at all, which would negatively affect our liquidity and may adversely impact our operations and results of operations.

| ▪ | Risks Related to the Automotive Industry. The automotive industry is our primary market. The COVID-19 pandemic has significantly disrupted, and is expected to continue to significantly disrupt, the global automotive industry and customer sales, production volumes and purchases of light vehicles by end consumers. Further, the spread of COVID-19 has created a

44

|  | significant disruption in the manufacturing, delivery and overall supply chain of automobile manufacturers and suppliers. In July 2020, IHS Markit forecasted light vehicle production volume for full-year 2020 of 69.5 million units, a decline of 21.8% from full-year 2019. Further, the COVID-19 pandemic has resulted in a temporary shutdown of substantially all of the major OEMs in our markets at various times in the first half of 2020. This has significantly reduced our year-to-date sales volumes and revenue as compared to our budget, and future sales volumes and revenue remain highly uncertain. Although automotive production has resume d, customer sales and production volumes may significantly decrease or may be very volatile due to global economic impacts and uncertainties. Any prolonged reduction in actual revenues and anticipated reduction in projected revenues may require us to evaluate our intangible assets or goodwill for impairment and incur impairment charges.

| ▪ | Risks Related to our Supply Chain and our Manufacturing Operations. The COVID-19 pandemic has adversely impacted our ability to manufacture products and obtain materials from our supply chain. We and our suppliers have experienced facility closures, work stoppages, travel restrictions, implementation of precautionary health and safety measures and other restrictions. We have experienced extended work stoppages in Asia, and subsequent suspension of vehicle production by our OEM customers in North America and Europe, as the pandemic spread to those regions and governmental authorities initiated “lock-down” orders for all non-essential activities. Due to the COVID-19 pandemic, a significant portion of our employees are now working from home, while under shelter-in-place orders or other restrictions, which may harm our ability to manage our business and increase operational risk, including increased cyber security attacks and reduced ability to implement security measures. Our manufacturing operations resumed production under enhanced public health procedures, including temperature screening of employees before entry into facilities, deep cleaning of facilities after each shift, and the provision of personal protective equipment. Further, companies in our global supply chain are subject to distinct legislative and regulatory requirements and limitations. Certain companies in our supply chain have had significant employee layoffs or furloughs and have significant financial distress, and some may determine to cease operations or restructure their business. Although our business operations have resumed, our suppliers may not be able to manufacture the materials and products we require according to our schedule and specifications, and we may need to seek alternate suppliers, which may be more expensive or may result in delays. We expect that a portion of our employees may not want to or be able to return to work or continue to work when permitted due to health, safety, family or otherwise. As a result, we and our supply chain may operate significantly below capacity for an uncertain period of time, each of which could significantly adversely affect our business, results of operations, financial condition, cash flows, liquidity and stock price.

| ▪ | Risks Related to our Customers. COVID-19 has and will continue to have a significant adverse impact on the growth, viability and financial stability of our customers, including the OEMs and Tier 1 automotive suppliers to which our products are supplied. In addition to many of the risks noted above that apply to our customers regarding the automotive industry generally and our supply chain, we expect to continue to experience a delay in our collection of accounts receivable balances from our customers, which may be significant and would be at risk in the event of their bankruptcy or other restructuring.

| ▪ | Risks Related to our Growth Prospects. Our ability to execute our business strategy through the pursuit of business ventures, acquisitions, and strategic alliances or dispositions has been, and will likely continue to be, significantly adversely impacted by COVID-19 and global economic conditions. While we continue to believe in our long-term growth strategy and prospects, we are limiting certain growth opportunities in the near term to conserve cash, including limiting the review of merger and acquisition opportunities and certain research and development activities. We also believe that new business awards will be subject to increased risk of future change as we look to convert awards into revenue. Further, a sustained decline in automotive production may delay or reduce our returns on research and development investments, which could significantly adversely affect our business, results of operations, financial condition, cash flows, liquidity and stock price.

| ▪ | Risks Related to Tax Matters. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer-side social security payroll taxes, the allowance of a five-year net operating loss carryback period and the temporary suspension of the 80% net operating loss limitation, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. We currently expect to defer the payment of payroll taxes each quarter for the remainder of 2020, with such taxes to be paid in the fourth quarters of 2021 and 2022 as permitted by the CARES Act. We continue to examine the impacts the CARES Act may have on our business, but the extent to which we will benefit from the tax provisions in the CARES Act is currently unclear.

In addition to the risks specifically described above, the COVID-19 pandemic has exacerbated and precipitated the other risks described in our Annual Report on Form 10-K for the year ended December 31, 2019, and may continue to do so, in ways that we are

45

not currently able to predict, any of which could significantly adversely affect our business, results of operations, financial condition, cash flows, liquidity or stock price.

ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities During Second Quarter 2020

Period |  | (a) Total Number of Shares Purchased |  |  | (b) Average Price Paid Per Share |  |  | (c) Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs |  |  | (d) Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (1) |
April 1, 2020 to April 30, 2020 |  |  | — |  |  | $ | — |  |  |  | — |  |  |  | 74,225,938 |
May 1, 2020 to May 31, 2020 |  |  | — |  |  | $ | — |  |  |  | — |  |  |  | 74,225,938 |
June 1, 2020 to June 30, 2020 |  |  | — |  |  | $ | — |  |  |  | — |  |  |  | 74,225,938 |

(1) | The stock repurchase program authorizes Gentherm to repurchase shares up to $300 million. The stock repurchase program expires on December 16, 2020. The authorization of this stock repurchase program does not require that the Company repurchase any specific dollar value or number of shares and may be modified, extended or terminated by the Company’s Board of Directors at any time. In March 2020, the Company suspended it share repurchase program in order to preserve liquidity. However, repurchases under the share repurchase program may resume at management’s discretion and may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations.

46

ITEM 6. | EXHIBI TS

Exhibits to this Report are as follows:

|  |  |  |  |  | Incorporated by Reference |
Exhibit Number |  | Exhibit Description |  | Filed /Furnished Herewith |  | Form |  | Period Ending |  | Exhibit / Appendix Number |  | Filing Date
3.1 |  | Second Amended and Restated Articles of Incorporation of Gentherm Incorporated |  |  |  | 8-K |  |  |  | 3.2 |  | 3/5/18
3.2 |  | Amended and Restated Bylaws of Gentherm Incorporated |  |  |  | 8-K |  |  |  | 3.1 |  | 5/26/16
10.1* |  | Offer Letter between Gentherm Incorporated and Barb Runyon dated June 18, 2018 |  | X |  |  |  |  |  |  |  |
10.2* |  | Executive Relocation and Employment Agreement between Gentherm Incorporated and Paul Giberson dated June 6, 2019 |  | X |  |  |  |  |  |  |  |
10.3* |  | First Amendment to Executive Relocation and Employment Agreement between Gentherm Incorporated and Paul Giberson dated as of April 21, 2020 |  | X |  |  |  |  |  |  |  |
10.4* |  | Second Amendment to Employment Terms between Gentherm Incorporated and Phillip Eyler dated as of April 21, 2020 |  | X |  |  |  |  |  |  |  |
10.5* |  | First Amendment to Offer Letter Agreement between Gentherm Incorporated and Matteo Anversa dated as of April 21, 2020 |  | X |  |  |  |  |  |  |  |
10.6* |  | Amendment to the Gentherm Incorporated 2013 Equity Incentive Plan, effective as of May 21, 2020 |  |  |  | 8-K |  |  |  | 10.1 |  | 5/26/20
10.7* |  | Form of Restricted Stock Award Agreement (Director) under the Gentherm Incorporated 2013 Equity Incentive Plan |  | X |  |  |  |  |  |  |  |
10.8* |  | Amendment No. 1 to Summary of Non-Employee Director Compensation |  | X |  |  |  |  |  |  |  |
31.1 |  | Section 302 Certification – CEO |  | X |  |  |  |  |  |  |  |
31.2 |  | Section 302 Certification – CFO |  | X |  |  |  |  |  |  |  |
32.1** |  | Section 906 Certification – CEO |  | X |  |  |  |  |  |  |  |
32.2** |  | Section 906 Certification – CFO |  | X |  |  |  |  |  |  |  |
101.INS |  | Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  | X |  |  |  |  |  |  |  |
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document. |  | X |  |  |  |  |  |  |  |
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  | X |  |  |  |  |  |  |  |
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  | X |  |  |  |  |  |  |  |
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document. |  | X |  |  |  |  |  |  |  |
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  | X |  |  |  |  |  |  |  |
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document contained in Exhibit 101) |  | X |  |  |  |  |  |  |  |

* Indicates management contract or compensatory plan or arrangement.

** Documents are furnished not filed.

47

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| Gentherm Incorporated
| /s/ PHILLIP EYLER
| Phillip Eyler
| President and Chief Executive Officer
| (Principal Executive Officer)
| Date: August 4, 2020

| /s/ MATTEO ANVERSA
| Matteo Anversa
| Executive Vice President, Chief Financial Officer and Treasurer
| (Principal Financial Officer)
| Date: August 4, 2020

48